
Sysmex Corporation and Its Subsidiaries

*Consolidated Financial Statements as of and
for the Year Ended March 31, 2017
and Independent Auditor's Report*

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Sysmex Corporation:

We have audited the accompanying consolidated statement of financial position of Sysmex Corporation and its subsidiaries as of March 31, 2017, and the related consolidated statements of income, comprehensive income, changes in equity, and cash flows, all expressed in Japanese yen, for the year then ended, and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in Japan. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Sysmex Corporation and its subsidiaries as of March 31, 2017, and the consolidated results of their operations and their cash flows for the year then ended in accordance with International Financial Reporting Standards.

Convenience Translation

Our audit also comprehended the translation of Japanese yen amounts into U.S. dollar amounts and, in our opinion, such translation has been made in accordance with the basis stated in Note 2(5) to the consolidated financial statements. Such U.S. dollar amounts are presented solely for the convenience of readers outside Japan.

Deloitte Touche Tohmatsu LLC

June 23, 2017

Sysmex Corporation and its Subsidiaries

Consolidated Statement of Financial Position As of March 31, 2017

	Notes	Millions of Yen			Thousands of U.S. Dollars (Note 2)
		March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Assets					
Current assets					
Cash and cash equivalents	6	¥ 57,944	¥ 56,481	¥ 49,613	\$ 517,357
Trade and other receivables	7, 14, 27	63,084	57,652	53,662	563,250
Inventories	8	36,998	35,604	29,966	330,339
Other short-term financial assets	17, 27	528	615	298	4,714
Income taxes receivable		457	453	223	4,080
Other current assets	18	7,303	7,450	6,484	65,205
Total current assets		166,318	158,258	140,248	1,484,982
Non-current assets					
Property, plant and equipment	9	60,144	59,282	56,835	537,000
Goodwill	10	8,308	6,921	7,192	74,179
Intangible assets	10	21,228	16,682	11,598	189,536
Investments accounted for using the equity method	11	552	2,089	1,937	4,929
Trade and other receivables	7, 14, 27	8,813	6,476	3,901	78,688
Other long-term financial assets	17, 27	6,107	6,010	6,440	54,527
Asset for retirement benefits	16	666	582	960	5,946
Other non-current assets	18	2,095	1,928	1,717	18,705
Deferred tax assets	13	5,581	5,684	6,478	49,830
Total non-currents assets		113,499	105,659	97,062	1,013,384
Total assets		¥ 279,817	¥ 263,917	¥ 237,310	\$ 2,498,366

See notes to consolidated financial statements.

Sysmex Corporation and its Subsidiaries

Consolidated Statement of Financial Position As of March 31, 2017

	Notes	Millions of Yen			Thousands of U.S. Dollars (Note 2)
		March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Liabilities and equity					
Liabilities					
Current liabilities					
Trade and other payables	12, 27	¥ 24,376	¥ 26,824	¥ 22,776	\$ 217,643
Other short-term financial liabilities	14, 17, 27	956	788	1,001	8,536
Income taxes payable		2,915	6,511	9,418	26,027
Provisions	15	610	554	450	5,446
Advance received		6,418	10,431	10,357	57,304
Accrued expenses		8,330	6,864	8,137	74,375
Accrued bonuses		6,636	6,538	6,130	59,250
Other current liabilities	18	9,708	9,383	9,084	86,679
Total current liabilities		59,952	67,896	67,355	535,286
Non-current liabilities					
Long-term financial liabilities	14, 17, 27	549	734	342	4,902
Liability for retirement benefits	16	654	566	562	5,839
Provisions	15	2,318	2,341	2,312	20,696
Other non-current liabilities	18	3,527	3,192	3,094	31,491
Deferred tax liabilities	13	2,562	6,384	5,669	22,875
Total non-current liabilities		9,612	13,219	11,980	85,821
Total liabilities		69,564	81,116	79,336	621,107
Equity					
Equity attributable to owners of the parent					
Capital stock	19	11,611	11,016	10,483	103,670
Capital surplus	19	17,303	16,969	16,340	154,491
Retained earnings	19	188,506	159,375	130,183	1,683,089
Treasury stock	19	(289)	(285)	(280)	(2,580)
Other components of equity	19	(7,725)	(4,275)	1,246	(68,973)
Total equity attributable to owners of the parent		209,406	182,800	157,972	1,869,696
Non-controlling interests		845	0	0	7,545
Total equity		210,252	182,801	157,973	1,877,250
Total liabilities and equity		¥ 279,817	¥ 263,917	¥ 237,310	\$ 2,498,366

See notes to consolidated financial statements.

Sysmex Corporation and its Subsidiaries

Consolidated Statement of Income For the Year Ended March 31, 2017

	Notes	Millions of Yen		Thousands of U.S. Dollars (Note 2)
		2017	2016	2017
Net sales	5	¥ 249,899	¥ 252,622	\$ 2,231,241
Cost of sales	20	108,122	101,932	965,375
Gross profit		141,777	150,689	1,265,866
Selling, general and administrative expenses	20	75,401	74,571	673,223
Research and development expenses	20	15,554	15,409	138,875
Other operating income	21	1,277	610	11,402
Other operating expenses	21	397	588	3,545
Operating profit		51,701	60,729	461,616
Financial income	22	514	382	4,589
Financial expenses	22	372	96	3,321
Share of loss on equity method	11	(677)	(465)	(6,045)
Foreign exchange loss		(2,218)	(2,741)	(19,804)
Profit before tax		48,946	57,809	437,018
Income tax expenses	13	8,493	18,530	75,830
Profit		¥ 40,453	¥ 39,278	\$ 361,188
Profit attributable to				
Owners of the parent		40,636	39,278	362,821
Non-controlling interests		(182)	(0)	(1,625)
Profit		¥ 40,453	¥ 39,278	\$ 361,188
		Yen		U.S. Dollars
Earnings per share				
Basic	24	¥195.31	¥189.08	\$1.74
Diluted	24	194.74	188.30	1.74

See notes to consolidated financial statements.

Sysmex Corporation and its Subsidiaries

Consolidated Statement of Comprehensive Income For the Year Ended March 31, 2017

	Notes	Millions of Yen		Thousands of U.S. Dollars (Note 2)
		2017	2016	2017
Profit		¥ 40,453	¥ 39,278	\$ 361,188
Other comprehensive income (loss)				
Items that will not be reclassified subsequently to profit or loss				
Net gain (loss) on financial assets measured at fair value through other comprehensive income	23	158	(430)	1,411
Remeasurements of defined benefit plans	23	139	(536)	1,241
Total		298	(967)	2,661
Items that may be reclassified subsequently to profit or loss				
Exchange differences on translation of foreign operations	23	(3,606)	(5,091)	(32,196)
Share of other comprehensive income of investments accounted for using the equity method	11, 23	(0)		(0)
Total		(3,607)	(5,091)	(32,205)
Total other comprehensive income (loss)		(3,309)	(6,059)	(29,545)
Comprehensive income		¥ 37,144	¥ 33,219	\$ 331,643
Comprehensive income attributable to				
Owners of the parent		¥ 37,327	¥ 33,219	\$ 333,277
Non-controlling interests		(182)	(0)	(1,625)
Comprehensive income		¥ 37,144	¥ 33,219	\$ 331,643

See notes to consolidated financial statements.

Sysmex Corporation and its Subsidiaries

Consolidated Statement of Changes in Equity For the Year Ended March 31, 2017

	Millions of Yen								
	Notes	Equity attributable to owners of the parent					Total	Non-controlling interests	Total equity
		Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity			
As of April 1, 2015		¥ 10,483	¥ 16,340	¥130,183	¥ (280)	¥ 1,246	¥157,972	¥ 0	¥157,973
Profit				39,278			39,278	(0)	39,278
Other comprehensive income (loss)						(6,058)	(6,058)	(0)	(6,059)
Comprehensive income (loss)				39,278		(6,058)	33,219	(0)	33,219
Exercise of warrants	19, 26	533	316				849		849
Share-based payment transaction	26		312				312		312
Cash dividends	19			(9,549)			(9,549)		(9,549)
Purchase of treasury stock	19				(4)		(4)		(4)
Transfer to retained earnings	19			(536)		536			
Changes from business combination									
Equity transactions with non-controlling interests									
Total transactions with the owners		533	628	(10,086)	(4)	536	(8,391)		(8,391)
As of March 31, 2016		11,016	16,969	159,375	(285)	(4,275)	182,800	0	182,801
Profit				40,636			40,636	(182)	40,453
Other comprehensive income (loss)						(3,309)	(3,309)	(0)	(3,309)
Comprehensive income (loss)				40,636		(3,309)	37,327	(182)	37,144
Exercise of warrants	19, 26	594	333				928		928
Share-based payment transaction	26								
Cash dividends	19			(11,646)			(11,646)		(11,646)
Purchase of treasury stock	19				(3)		(3)		(3)
Transfer to retained earnings	19			141		(141)			
Changes from business combination	28							1,028	1,028
Equity transactions with non-controlling interests			0				0	(0)	
Total transactions with the owners		594	334	(11,505)	(3)	(141)	(10,721)	1,028	(9,692)
As of March 31, 2017		¥ 11,611	¥ 17,303	¥188,506	¥ (289)	¥ (7,725)	¥209,406	¥ 845	¥210,252

	Thousands of U.S. Dollars (Note 2)								
	Notes	Equity attributable to owners of the parent					Total	Non-controlling interests	Total equity
		Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity			
As of March 31, 2016		\$ 98,357	\$151,509	\$ 1,422,991	\$ (2,545)	\$ (38,170)	\$ 1,632,143	\$ 0	\$ 1,632,152
Profit				362,821			362,821	(1,625)	361,188
Other comprehensive income (loss)						(29,545)	(29,545)	(0)	(29,545)
Comprehensive income (loss)				362,821		(29,545)	333,277	(1,625)	331,643
Exercise of warrants	19, 26	5,304	2,973				8,286		8,286
Share-based payment transaction	26								
Cash dividends	19			(103,982)			(103,982)		(103,982)
Purchase of treasury stock	19				(27)		(27)		(27)
Transfer to retained earnings	19			1,259		(1,259)			
Changes from business combination	28							9,179	9,179
Equity transactions with non-controlling interests			0				0	(0)	
Total transactions with the owners		5,304	2,982	(102,723)	(27)	(1,259)	(95,723)	9,179	(86,536)
As of March 31, 2017		\$103,670	\$154,491	\$ 1,683,089	\$ (2,580)	\$ (68,973)	\$ 1,869,696	\$ 7,545	\$ 1,877,250

See notes to consolidated financial statements.

Sysmex Corporation and its Subsidiaries

Consolidated Statement of Cash Flows For the Year Ended March 31, 2017

	Notes	Millions of Yen		Thousands of U.S. Dollars (Note 2)
		2017	2016	2017
Operating activities				
Profit before tax		¥ 48,946	¥ 57,809	\$ 437,018
Depreciation and amortization		12,381	12,110	110,545
Interest and dividend income		(425)	(335)	(3,795)
Interest expenses		104	46	929
Share of loss on equity method		677	465	6,045
Increase in trade receivables		(6,368)	(5,476)	(56,857)
Increase in inventories		(2,104)	(6,775)	(18,786)
(Decrease) increase in trade payables		(2,483)	4,145	(22,170)
Decrease/increase in consumption taxes receivable/payable		817	(903)	7,295
Decrease (increase) in asset for retirement benefits		117	(418)	1,045
(Decrease) increase in advance received		(3,635)	687	(32,455)
Increase in accrued bonuses		107	577	955
Other - net		634	(884)	5,661
Subtotal		48,770	61,047	435,446
Interest and dividend received		415	356	3,705
Interest paid		(85)	(31)	(759)
Income taxes paid		(16,268)	(19,578)	(145,250)
Net cash provided by operating activities		32,832	41,794	293,143
Investing activities				
Purchase of property, plant and equipment		(11,682)	(13,685)	(104,304)
Proceeds from sales of property, plant and equipment		200	107	1,786
Purchase of intangible assets		(7,424)	(8,399)	(66,286)
Purchase of investments in equity instruments		(632)	(633)	(5,643)
Acquisitions of subsidiaries or other businesses	28	(1,453)	(403)	(12,973)
Net decrease in short-term loans receivable		1,930		17,232
Other - net		(338)	(836)	(3,018)
Net cash used in investing activities		(19,400)	(23,850)	(173,214)
Financing activities				
Exercise of warrants		928	849	8,286
Dividends paid	19	(11,646)	(9,549)	(103,982)
Other - net		(148)	(55)	(1,321)
Net cash used in financing activities		(10,866)	(8,755)	(97,018)
Foreign currency translation adjustments on cash and cash equivalents				
		(1,102)	(2,320)	(9,839)
Net increase in cash and cash equivalents		1,462	6,868	13,054
Cash and cash equivalents, beginning of year		56,481	49,613	504,295
Cash and cash equivalents, end of year		¥ 57,944	¥ 56,481	\$ 517,357

See notes to consolidated financial statements.

Sysmex Corporation and its Subsidiaries

Notes to Consolidated Financial Statements As of and for the Year Ended March 31, 2017

1. REPORTING ENTITY

Sysmex Corporation (the "Company") is incorporated in Japan. The address of its registered headquarters is in Chuo-ku, Kobe. The consolidated financial statements of the Company have an annual closing date of March 31 and comprise the Company and its subsidiaries (collectively, the "Group") and equity interests in associates and joint ventures. The Group and the Company's associates and joint ventures are primarily engaged in the "health care business," providing diagnostic products and related services.

2. BASIS OF PREPARATION

(1) Compliance of the consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") and first-time adoption

The Company meets the requirements of a "specified company" as set forth in Article 1-2 of the "Ordinance on Terminology, Forms, and Preparation Methods of Consolidated Financial Statements." Accordingly, the Company has prepared the consolidated financial statements in accordance with IFRS pursuant to the provisions of Article 93 of the ordinance.

The Group has adopted IFRS from the current fiscal year (the year beginning April 1, 2016, and ended March 31, 2017), and it is the first time to disclose the annual consolidated financial statements in accordance with IFRS. The date of transition to IFRS was April 1, 2015, and the Group has applied IFRS 1 "First-time Adoption of International Financial Reporting Standards." ("IFRS 1").

The effects of the transition to IFRS on financial position, financial performance, and cash flows are stated in "33. DISCLOSURES ON TRANSITION TO IFRS."

The consolidated financial statements of the Company were approved by Hisashi Ietsugu, chairman and CEO, on June 23, 2017.

(2) Basis for measurement

The consolidated financial statements have been prepared on a historical cost basis, except for certain assets, liabilities, and financial instruments that are measured at fair value, as stated in "3. SIGNIFICANT ACCOUNTING POLICIES."

(3) Presentation currency

The consolidated financial statements are presented in Japanese yen, the functional currency of the Company, with amounts rounded down to the nearest million.

(4) Use of estimates and judgments

In the preparation of the consolidated financial statements in accordance with IFRS, management has used judgments, estimates, and assumptions that affect the application of the accounting policies and the reported amounts of assets, liabilities, income, and expenses. These estimates and assumptions are based on the judgments of management, which take into account historical experience and various factors that are believed reasonable as of the reporting date. However, actual results in the future may differ from these estimates and assumptions.

The estimates and the underlying assumptions are reviewed on an ongoing basis, and the effects of a change in an accounting estimate are recognized prospectively by including it in profit or loss in the period of the change and future periods.

The judgments, estimates, and assumptions that materially affect the amounts recognized in the consolidated financial statements are as follows:

- Estimated useful lives and residual values of property, plant and equipment and intangible assets (Refer to "9. PROPERTY, PLANT AND EQUIPMENT" and "10. GOODWILL AND INTANGIBLE ASSETS")
- Impairment of property, plant and equipment; goodwill; and intangible assets (Refer to "9. PROPERTY, PLANT AND EQUIPMENT" and "10. GOODWILL AND INTANGIBLE ASSETS")
- Recoverability of deferred tax assets (Refer to "13. INCOME TAXES")

- Measurements of defined benefit obligations (Refer to "16. POST-EMPLOYMENT BENEFITS")
- Revenues (Refer to "3. SIGNIFICANT ACCOUNTING POLICIES, (15) Revenues")
- Fair values of financial instruments (Refer to "27. FINANCIAL INSTRUMENTS")
- Fair values of assets acquired and liabilities assumed in a business combination (Refer to "28. BUSINESS COMBINATIONS")
- Evaluation of a contingent consideration in a business combination (Refer to "28. BUSINESS COMBINATIONS")

(5) U.S. dollar amounts

The consolidated financial statements are stated in Japanese yen, the currency of the country in which the Company is incorporated and operates. The translations of Japanese yen amounts into U.S. dollar amounts are included solely for the convenience of readers outside Japan and have been made at the rate of ¥112 to \$1, the approximate rate of exchange at March 31, 2017. U.S. dollar amounts are rounded down to the nearest thousand. Such translations should not be construed as representations that the Japanese yen amounts could be converted into U.S. dollars at that or any other rate.

3. SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies, unless stated otherwise, apply to all periods stated in the consolidated financial statements:

(1) Basis of consolidation

1) Subsidiaries

A subsidiary is an entity controlled by the Company. The Company controls an entity when it has exposure or rights to variable returns from its involvement in an entity and has the ability to use its power over an entity to affect such returns.

The financial statements of subsidiaries are included in the Company's consolidated financial statements from the date the Company obtains control to the date the Company loses control.

All subsidiaries that are included in the Group adopt common accounting policies.

Intragroup balances of receivables and payables, amounts of intragroup transactions, and any unrealized gains arising from intragroup transactions have been eliminated in preparing the consolidated financial statements.

Changes in the ownership interest in subsidiaries that do not result in loss of control are accounted for as equity transactions. If control over a subsidiary is lost, gains and losses arising from the loss of control are recognized in net profit or loss.

2) Associates and joint ventures

An associate is an entity over which the Company has significant influence, but does not have control over the financial and operating policies of such entity.

A joint venture is a joint arrangement between two or more parties that have joint control, whereby each party to the arrangement has a right to the net assets of the arrangement.

Investments in associates and joint ventures are initially recognized at cost at the time of acquisition and accounted for using the equity method from the date the Company obtains significant influence to the date the Company loses significant influence.

(2) Business combinations

Business combinations are accounted for using the acquisition method.

The identifiable assets and liabilities of the acquired entity are measured at their acquisition-date fair values.

If the cost of an acquisition, which includes the consideration transferred, the amount of non-controlling interests in the acquired entity, and the acquisition-date fair value of equity interests in the acquired entity previously held, exceeds the net value of identifiable assets and liabilities at the acquisition date, goodwill is measured at the excess amount. If the net value of identifiable assets and liabilities at the acquisition date exceeds the cost of an acquisition, the excess amount is recognized in net profit or loss. The consideration transferred is calculated as the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree, and the equity interests issued by the acquirer, including the fair values of the assets or liabilities arising from a contingent consideration arrangement. Acquisition-related costs are recognized as expenses in the periods in which the costs were incurred.

Non-controlling interests are measured either at fair value or at the present ownership instruments' proportionate share in the recognized amount of the acquiree's identifiable net assets, which is determined for each business combination.

(3) Foreign currency translation

1) Foreign currency transactions

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the date of the transaction.

At the end of each reporting period, foreign currency monetary items are translated using the closing rate. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was measured.

Exchange differences arising from such translation or settlement are recognized in net profit or loss. However, exchange differences arising from financial assets measured at fair value through other comprehensive income are recognized in other comprehensive income.

2) Foreign operations

The assets and liabilities of foreign operations are translated into Japanese yen at the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Japanese yen at the average rates of exchange for the year, unless there are material fluctuations in exchange rates. Exchange differences arising from such translation are recognized in other comprehensive income.

When foreign operations are disposed, the cumulative exchange differences related to such foreign operations are reclassified to net profit or loss at the time of disposal.

(4) Financial instruments

The Group has early adopted IFRS 9 "Financial Instruments" (revised in July 2014).

1) Financial assets

(i) Initial recognition and measurement

Financial assets are classified into financial assets measured at amortized cost and financial assets measured at fair value at initial recognition.

Financial assets that meet both of the following conditions are measured at amortized cost, and all other financial assets are measured at fair value.

(a) The financial asset is held in order to collect contractual cash flows;

(b) The contractual terms of the financial asset gives rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Equity instruments measured at fair value, excluding equity instruments held for trading that are required to be measured at fair value through profit or loss, shall be designated either as measured at fair value through profit or loss or measured at fair value through other comprehensive income for each equity instrument at the initial acquisition and subsequently to apply such designation.

In the case of financial assets not at fair value through profit or loss, the financial assets are measured at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets at initial recognition. However, trade receivables, which do not contain a material financial component, are measured at the transaction price.

Financial assets, such as stocks and bonds, are initially recognized on the contract date. All other financial assets are initially recognized on the transaction date.

(ii) Subsequent measurement

After initial recognition, financial assets are measured according to their classification as follows:

(a) Financial assets measured at amortized cost

Financial assets measured at amortized cost are measured using the effective interest method. Amortized cost using the effective interest method and gains and losses upon derecognition are recognized in profit or loss.

(b) Financial assets measured at fair value

Changes in fair value of financial assets measured at fair value are recognized in profit or loss, except for equity instruments that have been designated as measured at fair value through other comprehensive income. Any changes in fair value are recognized in other comprehensive income and transferred directly to retained earnings when derecognized or where losses are expected to be realized.

(iii) Derecognition

Financial assets are derecognized when the contractual rights to the cash flows from the financial assets are expired or transferred, and substantially all the risks and rewards of ownership of such financial assets are transferred.

2) Impairment of financial assets

In terms of financial assets measured at amortized cost, an assessment is made at each reporting date as to whether or not the credit risk on financial assets has increased significantly since the initial recognition, and the following amounts are recognized as an impairment loss depending on whether or not a significant increase in credit risk has occurred since the initial recognition:

(i) If credit risk has not increased significantly since initial recognition:

Amount equal to 12-month expected credit losses

(ii) If credit risk has increased significantly since initial recognition:

Amount equal to lifetime expected credit losses

However, for trade receivables and lease receivables, impairment losses in the amount equivalent to lifetime expected credit losses are recognized, regardless of whether the credit risk has increased significantly since initial recognition.

Expected credit losses are calculated in the following manner:

(i) Trade receivables and lease receivables

• Assets for which credit risk has not increased significantly since initial recognition:

Expected credit losses are calculated by multiplying the probability of default expected to occur in the future of similar assets by the carrying amount.

• Assets for which credit risk has increased significantly since initial recognition and assets that fall under credit-impaired financial assets:

The recoverable amounts are estimated individually, and the difference between the recoverable amounts and the carrying amounts is recognized as expected credit loss.

(ii) Assets other than (i) above

• Assets for which credit risk has not increased significantly since initial recognition:

Expected credit losses are calculated by multiplying the probability of default expected to occur in the future of similar assets by the carrying amount.

• Assets for which credit risk has increased significantly since initial recognition and assets that fall under credit-impaired financial assets:

The recoverable amounts are estimated individually, and each expected credit loss is measured as the difference between the present value of such assets discounted by the initial effective interest rate and the carrying amount.

The carrying amount of financial assets for which an impairment loss has been recognized is reduced through loss allowance, and impairment loss is recognized in profit or loss. In addition, when the Group has no reasonable expectations of recovering a financial asset, the carrying amount of the financial asset is reduced directly and the corresponding allowance account is also reduced.

If, after recognition of an impairment loss, the amount of impairment loss is reduced, the amount of reduction of the impairment loss is reversed in net profit or loss through the allowance account.

3) Financial liabilities

(i) Initial recognition and measurement

Financial liabilities are classified into financial liabilities measured at amortized cost or at fair value through profit or loss at initial recognition. All financial liabilities are initially measured at fair value, except for financial liabilities measured at amortized cost, which are measured at the amount net of direct transaction costs.

(ii) Subsequent measurement

After initial recognition, financial liabilities are measured according to their classification as follows:

(a) Financial liabilities measured at amortized cost

Measured at amortized cost using the effective interest method. Amortized cost using the effective interest method and gains and losses upon derecognition are recognized in profit or loss.

(b) Financial liabilities measured at fair value through profit or loss

Measured at fair value. Any changes in fair value of financial liabilities measured at fair value are recognized in profit or loss.

(iii) Derecognition

Financial liabilities are derecognized when obligations specified in a contract are discharged, cancelled, or expired.

4) Derivatives and hedge accounting

Derivatives are initially recognized at fair value on the date the derivative contract is entered into and are subsequently remeasured at fair value.

The Group uses forward exchange contracts, and similar contracts, to manage the foreign currency exchange rate risk exposure of recognized financial assets and liabilities in order to fix the cash flows from future transactions.

Hedge accounting does not apply to any of the above derivatives. Accordingly, derivative financial instruments are classified as "financial assets measured at fair value through profit or loss."

5) Offsetting financial instruments

A financial asset and a financial liability are offset and the net amount is presented in the consolidated statement of financial position only when the Company or its subsidiaries currently have a legally enforceable right to set off the recognized amounts and intend either to settle on net basis or to realize the asset and settle the liability simultaneously.

6) Fair value measurements

IFRS 13 "Fair Value Measurement" categorizes the inputs used to measure fair value into the following three levels according to the extent to which the input is observable from the outside:

- Level 1: Quoted prices in active markets for identical assets or liabilities that can be accessible at the measurement date;
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3: Unobservable inputs for the asset or liability.

Valuation techniques used to measure fair value maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

(5) Cash and cash equivalents

Cash and cash equivalents include cash on hand, call deposits, and short-term investments that are readily convertible to cash, with original maturities of three months or less, and have no significant risk of changes in value.

(6) Inventories

Inventories are measured at the lower of cost, or net realizable value. Cost of inventories is calculated primarily based on the weighted-average cost formula and comprise all costs of purchase, cost of conversion, and other costs incurred in bringing the inventories to their present location and condition. Net realizable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

(7) Property, plant and equipment

1) Recognition and measurement

All property, plant and equipment are measured at their cost less any accumulated depreciation and impairment losses.

Cost includes any directly attributable costs of acquiring the assets and the initially estimated costs of dismantling and removing the assets and site restoration.

2) Depreciation

Depreciation of property, plant and equipment (other than land and other non-depreciable assets) is calculated using the straight-line method over the estimated useful life of each asset.

The estimated useful lives are as follows:

Buildings and structures:	31 to 50 years
Machinery, equipment, and vehicles:	5 to 11 years
Tools, furniture, and fixtures:	2 to 15 years

Leased assets are depreciated over the estimated useful lives of the assets if it is reasonably certain that ownership will be transferred by the end of the lease term, while leased assets for which it is not certain that ownership will be transferred are depreciated over the shorter of their estimated useful lives or their lease terms.

The depreciation methods, estimated useful lives, and residual values are reviewed at the end of the fiscal year and revised as necessary.

(8) Goodwill and intangible assets

1) Goodwill

Goodwill is presented at cost less accumulated impairment losses. Goodwill is not amortized, but is tested for impairment in each period. Measurement of goodwill at initial recognition is as stated in "(2) Business combinations."

2) Intangible assets

All intangible assets are measured at cost less any accumulated amortization and impairment losses.

An intangible asset arising from development is recognized only if the Group can demonstrate all of the following:

- (i) The technical feasibility of completing the intangible asset so that it will be available for use or sale.
- (ii) Its intention to complete the intangible asset and use or sell it.
- (iii) Its ability to use or sell the intangible asset.
- (iv) How the intangible asset will generate probable future economic benefits. Among other things, the Group can demonstrate the existence of a market for the output of the intangible asset or the intangible asset itself, or if it is to be used internally, the usefulness of the intangible asset.
- (v) The availability of adequate technical, financial, and other resources to complete the development and to use or sell the intangible asset.
- (vi) Its ability to measure reliably the expenditure attributable to the intangible asset during its development.

Intangible assets are amortized by the straight-line method over their estimated useful lives from the day on which the assets became available for use.

The estimated useful lives are as follows:

Software:	3 to 10 years
Development expenses:	3 to 15 years
Other intangible assets:	2 to 22 years

The amortization methods, estimated useful lives, and residual values are reviewed at the end of the fiscal year period and revised as necessary.

There are no intangible assets with indefinite useful lives.

(9) Impairment of non-financial assets

In terms of non-financial assets (other than inventories and deferred tax assets), an assessment is made at the end of each reporting period for any indications of impairment in each asset or cash-generating unit. If any such indication exists, the Group estimates the recoverable amount of the asset or the cash-generating unit.

Goodwill and intangible assets with indefinite useful lives are tested for impairment at least once a year, regardless of whether any indications of impairment exist, and an impairment test is conducted each time any such indications of impairment are identified.

As corporate assets do not independently generate cash inflows, when indications of impairment become apparent in corporate assets, impairment testing is conducted based on the recoverable amount of the cash-generating unit to which such assets belong.

The recoverable amount is calculated as the higher of the fair value, less costs of disposal, or the value in use. The value in use is the present value calculated by discounting the estimated future cash flows from the asset or cash-generating unit.

If the recoverable amount of the asset or cash-generating unit is less than its carrying amount, the carrying amount is reduced to the recoverable amount and the difference is recognized as impairment loss in profit or loss.

In terms of assets and cash-generating units, excluding goodwill for which impairment losses have been recognized in prior years, assessment is conducted at the end of each reporting period for any indications of the possibility of reversal of such impairment losses. If any such indication exists, the recoverable amount of the asset or cash-generating unit is estimated, and if the recoverable amount exceeds the carrying amount of the asset or cash-generating unit, impairment loss is reversed. Reversal is recognized in profit or loss up to the carrying amount, net of depreciation, that would have been determined if no impairment loss had been recognized in prior years.

Impairment loss recognized for goodwill is not reversed.

(10) Leases

Whether a contract is a lease or whether a contract contains a lease is determined based on the substance of the contract at the inception of the lease.

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership, while all other leases are classified as operating leases.

1) Lease as lessor

In finance lease transactions, the amount of net investment in the lease is recognized as lease receivables. Lease income is classified into collection of principal and the amount equivalent to interest income, and the amount equivalent to interest income is recognized as revenue in the consolidated statement of income.

In operating lease transactions, lease income is recognized as revenue over the lease term on a straight-line basis.

2) Lease as lessee

In finance lease transactions, lease assets and lease liabilities are recognized at the lower of the fair value of the leased property or the present value of minimum lease payments. Lease payments are allocated to finance costs and repayment of lease liabilities based on the interest method, and the finance costs are recognized as expenses in the consolidated statement of income.

In operating lease transactions, lease payments are recognized as an expense over the lease term on a straight-line basis. Lease incentives received are an integral part of the total lease payments and are recognized as a deduction from the lease payments over the lease term.

(11) Employee benefits

1) Post-employment benefits

The Group has defined benefit plans, defined contribution plans, and multi-employer plans.

(i) Defined benefit plans

Net defined benefit liabilities (assets) are calculated at the discounted present value of benefit obligations under such plans less the fair value of the plan assets. Any amount recorded as assets from this calculation is limited to the present value of any future economic benefit available in the form of refunds from the plans or reductions in future contributions to the plans. Defined benefit plan obligations are calculated using the projected unit credit method as the discounted present value of the amount of estimated future benefits. The discount rate is determined by reference to market yields on high-quality corporate bonds as of the end of the reporting period, which reflect the estimated timing and amount of payment of the benefits.

Current service costs and net interest expenses related to the net defined benefit liabilities (assets) are recognized in net profit or loss.

Prior service costs are recognized immediately in net profit or loss.

Remeasurements of net defined benefit liabilities (assets), including actuarial gains and losses, are recognized in other comprehensive income and are immediately reclassified from other comprehensive income to retained earnings.

(ii) Defined contribution plans

The contributions under the defined contribution plans are recognized as expenses in the period in which the employee renders the related service.

(iii) Multi-employer plans

Although the Company and certain of its subsidiaries have participated in a multi-employer defined benefit plan, sufficient information has not been available to use defined benefit accounting. Accordingly, the contribution amount is recognized as an expense similar to the contribution amounts under defined contribution plans.

2) Others

Short-term employee benefits are recognized as expenses in the period in which the employee renders the related service without discounting.

Long-term employee benefits are the amounts of future benefit received by employees as consideration for services rendered in the prior and current periods discounted to the present value.

Bonus payments and paid leave are recognized as liabilities in the estimated payment amount, where there is a legal or constructive obligation to pay and the obligation can be estimated reliably.

(12) Stock-based compensation

The Company has adopted a stock option plan as an incentive for members of the Managing Board, which is the board of directors of the Company, and a portion of its employees. Stock options are estimated at fair value as of the grant date and recognized as expenses from the grant date throughout the vesting period, while the corresponding amount is recognized as an increase in equity. The fair value of the vested stock options is calculated by taking into account the requirements of the stock option and using the Black-Scholes option-pricing model.

(13) Provisions

Provisions are recognized if a present legal or constructive obligation exists as a result of past event that can be estimated reliably and it is probable that an outflow of resources with economic benefits will be required to settle the obligation.

When the time value of money is material, a provision is measured at the present value of the amount required to settle the present obligation.

(14) Equity

1) Common stock

The amount of common stock issued by the Company is recognized in capital stock and capital surplus. Direct issue costs (net of tax effect) are deducted from equity.

2) Treasury stock

On the purchase of treasury stock, costs including direct transaction costs (net of tax effect) are deducted from equity. On the disposal of treasury stock, the consideration received is recognized as an increase in equity.

(15) Revenues

The Group is engaged in the sales of diagnostic instruments and reagents and the rendering of related services. This includes lease contracts for diagnostic instruments. Revenue is measured at the fair value of the consideration received less discount; rebate; and taxes, including consumption taxes.

1) Sale of goods

Revenue is recognized when the significant risks and rewards of ownership of goods have been transferred to the customer; neither continuing managerial involvement associated with ownership nor effective control is retained over the goods; there is a high probability that the economic benefits associated with the transaction will flow to the Group; and costs incurred and revenue in respect of the transaction can be measured reliably. Specifically, revenue is recognized at the time of shipment, customer receipt, or customer approval after inspection depending on when ownership and the risks thereof are transferred from the Group to the customer. Transactions in which the Group acts as an agent are presented on a net basis.

2) Rendering of services

Services provided by the Group are mainly services incidental to the sales of products, including repairs and subcontracting of short-term maintenance.

Revenues from such transactions are recognized when all of the following conditions are met depending on the stage of completion of the transaction at the end of the reporting period:

- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the entity;
- The stage of completion of the transaction at the end of the reporting period can be measured reliably; and
- The costs incurred or to be incurred in respect of the transaction can be measured reliably.

3) Multiple-element arrangements

The Group enters into multiple-element arrangements that include various elements combining instruments, reagents, maintenance services, etc. If the elements meet all of the following requirements, the Group allocates the consideration for the transaction to each element according to the relative fair value of each element and revenue is recognized for each element.

- Each element has a stand-alone value to the customer and
- The fair value of each element can be measured reliably.

If the above requirements are not met, revenue is deferred as a single independent accounting unit until the undelivered products or services are delivered.

4) Revenues from leases

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership, while all other leases are classified as operating leases.

Revenues from finance leases are recognized according to the same accounting policies as those applied to the sales of goods. Financial income is recognized based on the effective interest method from the inception of the lease term. The interest rate used in the calculation represents the discount rate that equalizes the aggregate present value of the minimum lease payments and the unguaranteed residual value with the sum of the fair value of the leased receivables and any initial direct costs of the lessor.

Revenues from operating leases are recognized in profit or loss on a straight-line basis over the lease term.

5) Dividend and interest income

Dividend income from investments is recognized when the shareholders' right to receive payment has been established. Interest income is recognized based on principal and applicable effective interest rate on an accrual basis.

(16) Government grants

Government grants are measured and recognized at fair value when there is reasonable assurance that the Group will comply with the conditions attached to the grant and that the grant will be received. Government grants related to income are recognized in revenue over the period the expenses, which the grant is intended to compensate, are incurred. For government grants related to assets, the amounts of the grants are deducted from the costs of the assets.

(17) Income tax expenses

Income tax expenses comprise current taxes and deferred taxes and are recognized in net profit or loss, excluding items related to business combinations and items that are directly recognized in other comprehensive income or equity.

Current taxes are calculated based on the estimated amounts to be paid to (recovered from) the tax authorities, using the tax rates and tax laws that have been enacted or substantively enacted by the end of reporting period.

Deferred taxes are recognized for temporary differences between the carrying amounts of assets and liabilities in the consolidated statement of financial position and their tax bases. Deferred taxes are not recognized for the following temporary differences:

- Temporary differences arising from the initial recognition of assets or liabilities in transactions that affect neither accounting profit nor taxable profit (tax loss), other than business combinations;
- Temporary differences associated with investments in subsidiaries and associates and joint arrangements where the timing of the reversal of the temporary differences can be controlled by the Group and it is probable that the temporary differences will not reverse in the foreseeable future; and
- Taxable temporary differences arising from the initial recognition of goodwill.

Deferred taxes are calculated at the tax rates that are expected to apply to the period when the temporary difference is reversed based on the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when the deferred tax assets and deferred tax liabilities relate to income taxes levied on the same taxable entity by the same tax authority.

Deferred tax assets are recognized for deductible temporary differences, unused tax losses, and tax credits carried forward only to the extent it is probable that there will be taxable profit against which the deferred tax asset may be utilized. Deferred tax assets are reviewed at the end of each reporting period, and the carrying amount of a deferred tax asset is reduced to the extent it is no longer probable that sufficient taxable profit will be available to allow the benefit of the deferred tax asset to be utilized.

(18) Earnings per share

Basic earnings per share are calculated by dividing profit for the fiscal period attributable to owners of the parent by the weighted-average number of common stock outstanding during the fiscal period, less the number of treasury stock during the fiscal period. Diluted earnings per share are calculated through adjustments for the effect of all potential dilutive common stock.

4. STANDARDS AND INTERPRETATIONS ISSUED BUT NOT YET APPLIED

New or revised major standards and interpretations issued by the date of approval of the consolidated financial statements but were not yet adopted by the Group are as follows. The Group is currently evaluating the potential impact of applying these standards and interpretations to its consolidated financial statements, which cannot be estimated at this point.

IFRS	Mandatory application (from the year beginning)	Year of application period	Details of new or revised standards and interpretations
IFRS 15 Revenue from Contracts with Customers	January 1, 2018	Year ending March 31, 2019	Revision of accounting treatment relating to revenue recognition
IFRS 16 Leases	January 1, 2019	Year ending March 31, 2020	Revision of accounting treatment relating to leases

5. SEGMENT INFORMATION

(1) Overview of reportable segments

The Group's reportable segments are the business units of the Group for which discrete financial information is available and whose operating results are regularly reviewed by the Managing Board to make decisions about resources to be allocated to the segment and assess its performance.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan by the Company and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established in those regions. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Regional headquarters and other domestic and overseas subsidiaries are independent management units that handle production and sales for each region.

Accordingly, the Group has five reportable segments comprising geographical segments based on manufacturing and sales systems: "Japan," the "Americas," "EMEA," "China," and the "Asia Pacific."

(2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows:

- Intersegment sales are determined based on market prices or costs of goods manufactured.
- Accounting policies of reporting segments are consistent with the Group's accounting policies noted in "3. SIGNIFICANT ACCOUNTING POLICIES."

Year ended March 31, 2017

	Reportable segment					Total	Adjustments (Note 1)	Consolidated (Note 2)
	Japan	Americas	EMEA	China	Asia Pacific			
(Unit: Millions of yen)								
Sales								
Sales to external customers	¥ 46,900	¥ 56,584	¥ 64,924	¥ 60,317	¥ 21,172	¥ 249,899		¥ 249,899
Intersegment sales	94,042	350	2,600	11	3	97,008	¥ (97,008)	
Total	140,942	56,935	67,525	60,328	21,176	346,908	(97,008)	249,899
Segment profit	35,673	3,204	4,994	3,597	1,845	49,315	2,386	51,701
Financial income								514
Financial expenses								372
Share of loss on equity method								(677)
Foreign exchange loss								(2,218)
Profit before tax								48,946
Income tax expenses								8,493
Profit								40,453
Other								
Depreciation and amortization (Note 3)	¥ 6,352	¥ 2,035	¥ 3,344	¥ 295	¥ 1,326	¥ 13,353	¥ (972)	¥ 12,381

Notes:

1. Segment profit adjustments of ¥2,386 million include negative ¥4 million for the elimination of intersegment transactions, ¥2,227 million for the unrealized gains on inventories, and ¥166 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. Depreciation and amortization adjustments of negative ¥972 million are adjustments relating to intersegment transactions.

Year ended March 31, 2016

								(Unit: Millions of yen)	
	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)	
	Japan	Americas	EMEA	China	Asia Pacific	Total			
Sales									
Sales to external customers	¥ 43,008	¥ 55,946	¥ 68,453	¥ 65,144	¥ 20,069	¥ 252,622		¥ 252,622	
Intersegment sales	101,012	866	1,929	5	105	103,918	¥ (103,918)		
Total	144,020	56,812	70,382	65,149	20,174	356,540	(103,918)	252,622	
Segment profit	43,668	1,947	4,317	5,883	2,335	58,151	2,578	60,729	
Financial income								382	
Financial expenses								96	
Share of loss on equity method								(465)	
Foreign exchange loss								(2,741)	
Profit before tax								57,809	
Income tax expenses								18,530	
Profit								39,278	
Other									
Depreciation and amortization (Note 3)	¥ 5,726	¥ 2,263	¥ 3,654	¥ 275	¥ 1,353	¥ 13,273	¥ (1,162)	¥ 12,110	

Notes:

1. Segment profit adjustments of ¥2,578 million include ¥15 million for the elimination of intersegment transactions, ¥2,309 million for the unrealized gains on inventories, and ¥253 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. Depreciation and amortization adjustments of negative ¥1,162 million are adjustments relating to intersegment transactions.

Year ended March 31, 2017

(Unit: Thousands of U.S. dollars)

	Reportable segment					Total	Adjustments (Note 1)	Consolidated (Note 2)
	Japan	Americas	EMEA	China	Asia Pacific			
Sales								
Sales to external customers	\$ 418,750	\$ 505,214	\$ 579,679	\$ 538,545	\$ 189,036	\$ 2,231,241		\$ 2,231,241
Intersegment sales	839,661	3,125	23,214	98	27	866,143	\$ (866,143)	
Total	1,258,411	508,348	602,902	538,643	189,071	3,097,393	(866,143)	2,231,241
Segment profit	318,509	28,607	44,589	32,116	16,473	440,313	21,304	461,616
Financial income								4,589
Financial expenses								3,321
Share of loss on equity method								(6,045)
Foreign exchange loss								(19,804)
Profit before tax								437,018
Income tax expenses								75,830
Profit								361,188
Other								
Depreciation and amortization (Note 3)	\$ 56,714	\$ 18,170	\$ 29,857	\$ 2,634	\$ 11,839	\$ 119,223	\$ (8,679)	\$ 110,545

Notes:

1. Segment profit adjustments of \$21,304 thousand include negative \$36 thousand for the elimination of intersegment transactions, \$19,884 thousand for the unrealized gains on inventories, and \$1,482 thousand for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. Depreciation and amortization adjustments of negative \$8,679 thousand are adjustments relating to intersegment transactions.

(3) Information about products and services

Sales of all products and services of the Group to external customers are as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Instruments	¥ 83,024	¥ 91,081	\$ 741,286
Reagents	131,250	126,436	1,171,875
Maintenance services	27,703	28,501	247,348
Others	7,921	6,603	70,723
Total	¥ 249,899	¥ 252,622	\$ 2,231,241

(4) Information about geographical areas

Information about geographical areas is as follows:

Sales to external customers

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Japan	¥ 43,467	¥ 39,846	\$ 388,098
America	51,904	50,056	463,429
China	60,334	65,189	538,696
Others	94,192	97,530	841,000
Total	¥ 249,899	¥ 252,622	\$ 2,231,241

Sales are classified by country based on the location of customers.

Non-current assets (excluding financial assets, asset for retirement benefit, and deferred tax assets)

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Japan	¥ 59,438	¥ 52,985	¥ 46,642	\$ 530,696
Germany	11,778	12,093	12,307	105,161
Others	20,561	19,735	18,394	183,580
Total	¥ 91,777	¥ 84,814	¥ 77,344	\$ 819,438

(5) Information about major customers

There are no customers who account for more than 10% of the consolidated sales.

6. CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Cash and cash equivalents	¥ 57,944	¥ 56,481	¥ 49,613	\$ 517,357
Total	¥ 57,944	¥ 56,481	¥ 49,613	\$ 517,357

7. TRADE AND OTHER RECEIVABLES

Trade and other receivables consist of the following:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Notes and trade receivable	¥ 60,616	¥ 55,505	¥ 52,372	\$ 541,214
Lease receivables	11,486	8,535	5,413	102,554
Accounts receivable - other	380	680	356	3,393
Loss allowance	(585)	(592)	(579)	(5,223)
Total	¥ 71,898	¥ 64,129	¥ 57,563	\$ 641,946

Trade and other receivables are classified as financial assets measured at amortized cost.

8. INVENTORIES

Inventories consist of the following:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Merchandise and finished goods	¥ 28,865	¥ 27,040	¥ 22,754	\$ 257,723
Work in process	2,819	2,982	2,977	25,170
Raw materials and supplies	5,313	5,581	4,234	47,438
Total	¥ 36,998	¥ 35,604	¥ 29,966	\$ 330,339

The costs of inventories recognized as an expense under "Cost of sales" for the years ended March 31, 2017 and 2016, were ¥75,822 million (\$676,982 thousand) and ¥71,302 million, respectively.

Write-downs of inventories recognized as an expense for the years ended March 31, 2017 and 2016, were ¥179 million (\$1,598 thousand) and ¥186 million, respectively.

9. PROPERTY, PLANT AND EQUIPMENT

Reconciliations of carrying amount from the beginning balances to the ending balances and year-end balances of acquisition cost, accumulated depreciation, and accumulated impairment losses on property, plant and equipment are as follows:

Carrying amount

	Millions of Yen					
	Buildings and structures	Machinery and vehicles	Furniture and fixtures	Land	Construction in progress	Total
As of April 1, 2015	¥ 22,330	¥ 3,579	¥ 16,445	¥ 10,377	¥ 4,103	¥ 56,835
Additions	1,810	734	8,432	62	2,764	13,803
Additions by business combinations						
Depreciation	(2,142)	(406)	(6,033)			(8,582)
Sale or disposal	(47)	(17)	(108)		(130)	(303)
Exchange differences on translation of foreign currency	(329)	(113)	(950)	(9)	(65)	(1,467)
Transfer	3,456	403	(209)	1	(4,655)	(1,002)
As of March 31, 2016	25,077	4,179	17,576	10,431	2,016	59,282
Additions	1,472	275	6,931	76	3,133	11,888
Additions by business combinations	40		180			220
Depreciation	(1,940)	(650)	(5,865)			(8,455)
Sale or disposal	(69)	(2)	(482)	(2)	(0)	(557)
Exchange differences on translation of foreign currency	(242)	(66)	(770)	(10)	24	(1,066)
Transfer	1,275	91	(579)		(1,955)	(1,167)
As of March 31, 2017	¥ 25,612	¥ 3,827	¥ 16,991	¥ 10,494	¥ 3,218	¥ 60,144

	Thousands of U.S. Dollars					
	Buildings and structures	Machinery and vehicles	Furniture and fixtures	Land	Construction in progress	Total
As of March 31, 2016	\$ 223,902	\$ 37,313	\$ 156,929	\$ 93,134	\$ 18,000	\$ 529,304
Additions	13,143	2,455	61,884	679	27,973	106,143
Additions by business combinations	357		1,607			1,964
Depreciation	(17,321)	(5,804)	(52,366)			(75,491)
Sale or disposal	(616)	(18)	(4,304)	(18)	(0)	(4,973)
Exchange differences on translation of foreign currency	(2,161)	(589)	(6,875)	(89)	214	(9,518)
Transfer	11,384	813	(5,170)		(17,455)	(10,420)
As of March 31, 2017	\$ 228,679	\$ 34,170	\$ 151,705	\$ 93,696	\$ 28,732	\$ 537,000

Acquisition cost

	Millions of Yen					
	Buildings and structures	Machinery and vehicles	Furniture and fixtures	Land	Construction in progress	Total
As of April 1, 2015	¥ 38,436	¥ 10,636	¥ 49,405	¥ 10,487	¥ 4,138	¥ 113,104
As of March 31, 2016	43,028	10,971	50,740	10,540	2,050	117,331
As of March 31, 2017	45,128	10,972	50,207	10,596	3,250	120,154

	Thousands of U.S. Dollars					
	Buildings and structures	Machinery and vehicles	Furniture and fixtures	Land	Construction in progress	Total
As of March 31, 2017	\$ 402,929	\$ 97,964	\$ 448,277	\$ 94,607	\$ 29,018	\$ 1,072,804

Accumulated depreciation and accumulated impairment losses

	Millions of Yen					
	Buildings and structures	Machinery and vehicles	Furniture and fixtures	Land	Construction in progress	Total
As of April 1, 2015	¥ (16,106)	¥ (7,056)	¥ (32,960)	¥ (110)	¥ (35)	¥ (56,269)
As of March 31, 2016	(17,951)	(6,792)	(33,163)	(108)	(34)	(58,049)
As of March 31, 2017	(19,515)	(7,144)	(33,215)	(101)	(32)	(60,010)

	Thousands of U.S. Dollars					
	Buildings and structures	Machinery and vehicles	Furniture and fixtures	Land	Construction in progress	Total
As of March 31, 2017	\$ (174,241)	\$ (63,786)	\$ (296,563)	\$ (902)	\$ (286)	\$ (535,804)

Depreciation of property, plant and equipment is included in "Cost of sales;" "Selling, general and administrative expenses;" and "Research and development expenses" in the consolidated statement of income.

Of the balances of property, plant and equipment as of March 31, 2017, March 31, 2016, and the date of transition to IFRS, ¥217 million (\$1,938 thousand), ¥243 million, and ¥302 million, respectively, were pledged as collateral for loans payable.

For commitments for purchases of property, plant and equipment, please refer to "30. COMMITMENTS FOR EXPENDITURES."

The carrying amounts of leased assets under finance leases included in property, plant and equipment are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Machinery and equipment	¥ 16	¥ 21	¥ 21	\$ 143
Furniture and fixtures	537	690		4,795
Total	¥ 553	¥ 712	¥ 21	\$ 4,938

10. GOODWILL AND INTANGIBLE ASSETS

(1) Reconciliations of the carrying amount from the beginning balances to the ending balances and year-end balances of acquisition cost, accumulated amortization, and accumulated impairment losses on goodwill and intangible assets

The movement of the carrying amount from the beginning balances to the ending balances and year-end balances of acquisition cost, accumulated amortization, and accumulated impairment losses on goodwill and intangible assets is as follows:

Carrying amount

	Millions of Yen				
	Goodwill	Intangible assets			
		Software	Development expenses	Other	Total
As of April 1, 2015	¥ 7,192	¥ 6,297	¥ 3,122	¥ 2,177	¥ 11,598
Acquisitions		4,454	2,866	1,325	8,645
Additions by business combinations					
Amortization		(2,146)	(991)	(249)	(3,386)
Sale or disposal		(38)		(0)	(38)
Exchange differences on translation of foreign currency	(271)	(97)		(38)	(136)
As of March 31, 2016	6,921	8,470	4,997	3,214	16,682
Acquisitions		4,029	2,753	873	7,656
Additions by business combinations	1,655	18		803	821
Amortization		(2,878)	(365)	(520)	(3,765)
Sale or disposal		(20)	(35)		(56)
Exchange differences on translation of foreign currency	(267)	(33)		(75)	(109)
As of March 31, 2017	¥ 8,308	¥ 9,584	¥ 7,350	¥ 4,293	¥ 21,228

	Thousands of U.S. Dollars				
	Goodwill	Intangible assets			
		Software	Development expenses	Other	Total
As of March 31, 2016	\$ 61,795	\$ 75,625	\$ 44,616	\$ 28,696	\$ 148,946
Acquisition		35,973	24,580	7,795	68,357
Additions by business combinations	14,777	161		7,170	7,330
Amortization		(25,696)	(3,259)	(4,643)	(33,616)
Sale or disposal		(179)	(313)		(500)
Exchange differences on translation of foreign currency	(2,384)	(295)		(670)	(973)
As of March 31, 2017	\$ 74,179	\$ 85,571	\$ 65,625	\$ 38,330	\$ 189,536

Acquisition cost

	Millions of Yen				
	Goodwill	Intangible assets			
		Software	Development expenses	Other	Total
As of April 1, 2015	¥ 10,912	¥ 17,215	¥ 3,842	¥ 4,969	¥ 26,027
As of March 31, 2016	10,559	21,076	6,226	6,078	33,381
As of March 31, 2017	11,730	24,591	8,321	7,462	40,376

	Thousands of U.S. Dollars				
	Goodwill	Intangible assets			
		Software	Development expenses	Other	Total
As of March 31, 2017	\$ 104,732	\$ 219,563	\$ 74,295	\$ 66,625	\$ 360,500

Accumulated amortization and accumulated impairment losses

	Millions of Yen				
	Goodwill	Intangible assets			Total
		Software	Development expenses	Other	
As of April 1, 2015	¥ (3,720)	¥ (10,917)	¥ (720)	¥ (2,791)	¥ (14,428)
As of March 31, 2016	(3,637)	(12,606)	(1,228)	(2,864)	(16,699)
As of March 31, 2017	(3,421)	(15,007)	(971)	(3,168)	(19,147)

	Thousands of U.S. Dollars				
	Goodwill	Intangible assets			Total
		Software	Development expenses	Other	
As of March 31, 2017	\$ (30,545)	\$(133,991)	\$ (8,670)	\$ (28,286)	\$(170,955)

Amortization of intangible assets is included in "Cost of sales;" "Selling, general and administrative expenses;" and "Research and development expenses" in the consolidated statement of income.

Software includes internally developed software.

(2) Impairment losses

The Group tests impairment for goodwill at least once a year, and if any indications of impairment exist, impairment testing is conducted each time such indications of impairment become apparent.

The recoverable amount used in impairment testing of goodwill is measured at value in use. The value in use is determined by discounting to the present value of estimated future cash flows based on financial budgets of each cash-generating unit or a group of cash-generating units for one to five years, which are approved by management, and growth rates for the following: Growth rates are determined by taking into consideration the average long-term growth rate of the market or the country in which each cash-generating unit or group of cash-generating units operates (year ended March 31, 2017: 0.0%-3.0%; year ended March 31, 2016: 0.0%-3.0%). The discount rate is determined based on the after-tax weighted-average capital cost for the market or the country in which each cash-generating unit or group of cash-generating units operates (year ended March 31, 2017: 6.5%-14.7%; year ended March 31, 2016: 7.3%-14.0%).

The Group believes that even if the major assumptions used in impairment testing would change within a reasonably estimated range, it is unlikely that the recoverable amount falls below the carrying amount as of March 31, 2016, and the date of transition to IFRS. As of March 31, 2017, the recoverable amount of Sysmex Partec exceeds the carrying amount, but if its growth rate decreases by 1.3% or its discount rate increases by 0.8%, impairment is needed. The Group also believes that even if the significant assumptions used in impairment testing would change within a reasonably estimated range, it is unlikely that the recoverable amount falls below the carrying amount of each cash-generating unit or a group of cash-generating units as of March 31, 2017.

The carrying amounts of goodwill that has been allocated to cash-generating units are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Sysmex Partec	¥ 4,706	¥ 5,004	¥ 5,107	\$ 42,018
Sysmex Korea	1,665	1,636	1,803	14,866
Riken Genesis	1,655			14,777
Others	281	281	281	2,509
Total	¥ 8,308	¥ 6,921	¥ 7,192	\$ 74,179

11. DISCLOSURE OF INTERESTS IN OTHER ENTITIES

(1) Significant subsidiaries and associates

Significant subsidiaries and associates of the Company are as follows:

1) Subsidiaries

Company name	Segment	Location	Capital or investments	Line of business	Holding percentage of voting rights			Relationships					
					Direct (%)	Indirect (%)	Total (%)	Concurrent officers		Financial aid	Transactions in operations	Lease of facilities	Business partnership, etc.
								Officers (person)	Employee (person)				
Sysmex International Reagents Co., Ltd.	Japan	Nishi-ku, Kobe	Million JPY 300	Manufacture of in vitro diagnostic reagents	100		100		5		Manufacture of in-house reagents	Lease of buildings and facilities	
Sysmex America, Inc.	Americas	Illinois, USA	Thousand USD 22,000	Sales of in vitro diagnostic instruments and reagents	100		100	1	2		Sales of in-house products, etc.		
Sysmex Europe GmbH	EMEA	Norderstedt, Germany	Thousand EUR 820	Sales of in vitro diagnostic instruments and sales and manufacture of in vitro diagnostic reagents	100		100	1	2		Sales and manufacture of in-house reagents, etc.		
Sysmex Deutschland GmbH	EMEA	Norderstedt, Germany	Thousand EUR 2,050	Sales of in vitro diagnostic instruments and reagents	100		100		1		Sales of in-house products		
Sysmex UK Limited	EMEA	Milton Keynes, United Kingdom	Thousand 400	Sales of in vitro diagnostic instruments and reagents	100		100		1		Sales of in-house products		
Sysmex France S.A.S.	EMEA	Villepinte, France	Thousand EUR 2,457	Sales of in vitro diagnostic instruments and reagents	18.6	81.4	100		1		Sales of in-house products		
Sysmex Suisse AG	EMEA	Zürich Switzerland	Thousand CHF 50	Sales of in vitro diagnostic instruments and reagents			100				Sales of in-house products		
Sysmex Shanghai Ltd.	China	Shanghai, China	Thousand USD 1,000	Sales of in vitro diagnostic instruments and reagents	100		100	1	4		Sales of in-house products, etc.		
Sysmex Asia Pacific Pte Ltd.	Asia Pacific	Singapore	Thousand SGD 11,500	Sales of in vitro diagnostic instruments and sales and manufacture of in vitro diagnostic reagents	100		100	1	2		Sales and manufacture of in-house reagents, etc.		
Sysmex Korea Co., Ltd.	Asia Pacific	Seoul, Korea	Thousand KRW 190,000	Sales of in vitro diagnostic instruments and reagents	100		100		3		Sales of in-house products		
Other 52 subsidiaries													

2) Associates

Company name	Segment	Location	Capital or investments	Line of business	Holding percentage of voting rights			Relationships					
					Direct (%)	Indirect (%)	Total (%)	Concurrent officers		Financial aid	Transactions in operations	Lease of facilities	Business partnership, etc.
								Officers (person)	Employee (person)				
Sysmex bioMérieux Co., Ltd.	Japan	Shinagawa-ku, Tokyo	Million JPY 480	Sales of in vitro diagnostic reagents and import and sales of medical instruments	34		34		3		Sales of in-house products, etc.		Business partnership on sales and services
Medicaroid Corporation	Japan	Chuo-ku, Kobe	Million JPY 1,260	Marketing, development, manufacture, and sales of medical robots	50		50	1	2				

(2) Investments accounted for using the equity method

The Group accounts for investments in associates and joint ventures using the equity method. The Group has no material associates or joint ventures.

The carrying amounts of investments in associates which are immaterial individually and the financial information thereof are as shown below. The following represents amounts after adjustments using the equity method:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
	Carrying amount	¥ 255	¥ 1,717	¥ 1,929
Comprehensive income	Millions of Yen			Thousands of U.S. Dollars
	2017	2016		2017
	Profit	¥ 21	¥ (211)	
Total	¥ 21	¥ (211)		\$ 188

The carrying amounts of investments in joint ventures which are immaterial individually, and the financial information thereof, are as shown below. The following represents amounts after adjustments using the equity method:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Carrying amount	¥ 296	¥ 371	¥ 7	\$ 2,643

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Comprehensive income			
Profit	¥ (699)	¥ (253)	\$ (6,241)
Other comprehensive income	(0)		(0)
Total	¥ (699)	¥ (253)	\$ (6,241)

(3) Structured entities

The Group operates investment activities through investment partnerships. Such partnerships provide their investees with cash raised from members of the partnerships mainly in the form of investments, and have been designed so that voting or similar rights are not the dominant factor in deciding who controls the entity.

The Group invests in unconsolidated structured entities, such as investment funds and trusts, over which it does not have control with regard to operating policies such as those related to selecting investees.

The Company does not have any contractual obligations to provide any financial support to the unconsolidated structured entities. Therefore, the potential maximum loss exposure incurred from the involvement with such structured entities is limited to the total of the carrying amount of the Company's investment, which is as follows: The Company's maximum loss exposure represents the potential maximum loss amount and does not indicate the probability of occurrence.

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Other long-term financial assets	¥ 299	¥ 518	¥ 916	\$ 2,670

12. TRADE AND OTHER PAYABLES

Trade and other payables consist of the following:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Notes and trade payable	¥ 17,661	¥ 19,873	¥ 16,066	\$ 157,688
Accounts payable - other	6,714	6,950	6,710	59,946
Total	¥ 24,376	¥ 26,824	¥ 22,776	\$ 217,643

Trade and other payables are classified as financial liabilities measured at amortized cost.

13. INCOME TAXES

(1) Deferred taxes

1) Components of deferred tax assets and deferred tax liabilities

Components of deferred tax assets and deferred tax liabilities are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Deferred tax assets				
Loss allowance	¥ 142	¥ 108	¥ 84	\$ 1,268
Inventories	405	512	555	3,616
Unrealized intercompany profits	3,460	4,003	4,688	30,893
Property, plant and equipment	207	251	386	1,848
Intangible assets	1,052	927	930	9,393
Accrued enterprise tax	22	435	519	196
Accrued expenses	645	654	939	5,759
Accrued bonuses	1,265	1,302	1,205	11,295
Accrued paid leave	568	517	535	5,071
Liability for retirement benefits	133	112	117	1,188
Special contributions	649	678	704	5,795
Tax loss carryforwards	141	82	28	1,259
Other	1,869	1,594	1,343	16,688
Total deferred tax assets	¥ 10,565	¥ 11,182	¥ 12,039	\$ 94,330
Deferred tax liabilities				
Property, plant and equipment	329	651	875	2,938
Intangible assets	2,687	1,692	1,155	23,991
Financial assets measured at fair value through other comprehensive income	434	365	585	3,875
Investment loss for subsidiaries' capital reduction by corporate tax law	324	324	341	2,893
Asset for retirement benefits	203	178	309	1,813
Undistributed earnings of foreign subsidiaries (Note)	2,829	8,083	7,526	25,259
Other	737	587	435	6,580
Total deferred tax liabilities	¥ 7,546	¥ 11,882	¥ 11,230	\$ 67,375
Net deferred tax assets (liabilities)	¥ 3,018	¥ (700)	¥ 809	\$ 26,946

Note:

Regarding the "Agreement between Japan and the Federal Republic of Germany for the Elimination of Double Taxation with respect to Taxes on Income and to Certain Other Taxes and the Prevention of Tax Evasion and Avoidance," the necessary approval in Japan and Germany was completed on July 8, 2016, and the above tax agreement was substantively enacted. As a result of the acceptance of the agreement, withholding taxes regarding dividends from subsidiaries in Germany paid to the Company have been exempted since January 1, 2017. In accordance with the exemption of withholding taxes, deferred tax liabilities of ¥5,123 million (\$45,741 thousand) recognized for dividend withholding taxes were reversed during the second quarter of the fiscal year ended March 31, 2017.

The changes in net amounts of deferred tax assets (liabilities) are as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Beginning balance	¥ (700)	¥ 809	\$ (6,250)
Deferred tax expense	4,178	(2,016)	37,304
Deferred tax related to each item in other comprehensive income			
Net changes in fair value of financial assets measured at fair value through other comprehensive income	(69)	219	(616)
Remeasurement of defined benefit liabilities (assets)	(61)	259	(545)
Translation differences in foreign operation	(83)	28	(741)
Decrease associated with business combination	(246)		(2,196)
Ending balance	¥ 3,018	¥ (700)	\$ 26,946

- 2) Deductible temporary differences, tax loss carryforwards, and tax credits for which no deferred tax assets have been recognized

Deductible temporary differences, tax loss carryforwards, and tax credits for which no deferred tax assets have been recognized are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Deductible temporary differences	¥ 669	¥ 699	¥ 57	\$ 5,973
Tax loss carryforwards	7,345	3,413	1,072	65,580
Tax credits	7	7	76	63

Expiration dates for tax loss carryforwards for which deferred tax assets have not been recognized are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Within one year				
Between one year and two years				
Between two and three years				
Between three and four years				
More than five years	¥ 7,345	¥ 3,413	¥ 1,072	\$ 65,580
Total	¥ 7,345	¥ 3,413	¥ 1,072	\$ 65,580

- (2) Income tax expenses

- 1) Components of income tax expenses

Income tax expenses consist of the following:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Current tax expense	¥ 12,672	¥ 16,513	\$ 113,143
Deferred tax expense			
Occurrence and reversal of temporary differences (Note)	(5,521)	842	(49,295)
Effect of change in tax rates	30	225	268
Reassessment of recoverability of deferred tax assets	1,312	948	11,714
Total	¥ 8,493	¥ 18,530	\$ 75,830

Note:

In accordance with acceptance of the agreement, withholding taxes, deferred tax liabilities of ¥5,123 million (\$45,741 thousand) recognized for dividend withholding taxes were reversed during the second quarter of the fiscal year ended March 31, 2017. Please see (1) Deferred taxes 1) Components of deferred tax assets and deferred tax liabilities above for the details of the agreement.

2) Reconciliation of applicable tax rates

The Group is mainly subject to income tax, inhabitant tax, and enterprise tax based on which the effective statutory tax rates came to 30.8% and 33.0% for the years ended March 31, 2017 and 2016, respectively. However, foreign subsidiaries are subject to income taxes applicable to the jurisdictions in which they are located.

Following enactment by the Diet of the Act for Partial Revision of the Income Tax Act, etc. (Act No. 15 of 2016) and the Act for Partial Revision of the Local Tax Act, etc. (Act No. 13 of 2016) on March 29, 2016, statutory tax rates were lowered from the fiscal year commencing April 1, 2016. As a result, the effective statutory tax rate used for calculating deferred tax assets and deferred tax liabilities was lowered from the previous 33.0% to 30.8% for temporary differences that are expected to be utilized in the fiscal years commencing April 1, 2016, and 2017, and to 30.6% for temporary differences that are expected to be utilized in the fiscal year commencing April 1, 2018.

The reasons for the difference between the effective tax rate and the actual tax rate are as follows:

	2017	2016
Effective tax rates	30.8%	33.0%
Expenses not deductible for income tax purposes	0.5	0.8
Tax credit for research and other	(4.3)	(3.6)
Reassessment of recoverability of deferred tax assets	1.6	1.9
Tax effect on undistributed earnings of foreign subsidiaries	(10.7)	1.1
Different tax rates applied to foreign subsidiaries	(0.5)	(1.6)
Gain on step acquisitions	(0.3)	
Other	0.3	0.5
Actual tax rates	17.4%	32.1%

14. LEASES

(1) Lessor

1) Finance leases

The Group leases diagnostic instruments and others under finance leases.

Gross investment in leases, present value of minimum lease payments receivable, and adjustments relating to finance leases are as follows:

	Millions of Yen					
	Gross investment in leases			Present value of minimum lease payments receivable		
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017	March 31, 2016	Date of transition to IFRS
Not later than one year	¥ 3,020	¥ 2,275	¥ 1,623	¥ 2,587	¥ 1,960	¥ 1,379
Later than one year and not later than five years	8,705	6,375	4,047	7,103	5,202	2,993
Later than five years	799	547	161	669	461	94
Total	¥ 12,525	¥ 9,198	¥ 5,832	¥ 10,360	¥ 7,624	¥ 4,467
(Including unguaranteed residual value)	¥ 1,302	¥ 1,031	¥ 1,019			
Less:						
Unearned finance income	1,038	662	418			
Present value of unguaranteed residual value	1,126	911	946			
Present value of minimum lease payments receivable	10,360	7,624	4,467			

	Thousands of U.S. Dollars	
	Gross investment in leases	Present value of minimum lease payments receivable
	March 31, 2017	March 31, 2017
Not later than one year	\$ 26,964	\$ 23,098
Later than one year and not later than five years	77,723	63,420
Later than five years	7,134	5,973
Total	\$ 111,830	\$ 92,500
(Including unguaranteed residual value)	\$ 11,625	
Less:		
Unearned finance income	9,268	
Present value of unguaranteed residual value	10,054	
Present value of minimum lease payments receivable	92,500	

2) Operating leases

The Group leases diagnostic instruments and others under operating leases.

Future minimum lease payments expected to be received under non-cancellable operating leases are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
	Not later than one year	¥ 1,750	¥ 1,233	¥ 1,328
Later than one year and not later than five years	2,738	2,365	2,519	24,446
Later than five years	91	282	309	813
Total	¥ 4,579	¥ 3,882	¥ 4,157	\$ 40,884

(2) Lessee

1) Finance leases

The Group rents diagnostic instruments and others under finance leases.

Future minimum lease payments and the present value thereof are as follows:

	Millions of Yen					
	Future minimum lease payments			Present value of future minimum lease payments		
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017	March 31, 2016	Date of transition to IFRS
Not later than one year	¥ 230	¥ 236	¥ 61	¥ 170	¥ 149	¥ 49
Later than one year and not later than five years	588	819	143	512	687	114
Later than five years	22	49	87	22	46	81
Total	¥ 842	¥ 1,105	¥ 292	¥ 704	¥ 883	¥ 245
Less:						
Amount equivalent to interest	¥ 137	¥ 222	¥ 47			
Present value of future minimum lease payments	704	883	245			

	Thousands of U.S. Dollars	
	Future minimum lease payments	Present value of future minimum lease payments
	March 31, 2017	March 31, 2017
Not later than one year	\$ 2,054	\$ 1,518
Later than one year and not later than five years	5,250	4,571
Later than five years	196	196
Total	\$ 7,518	\$ 6,286
Less:		
Amount equivalent to interest	\$ 1,223	
Present value of future minimum lease payments	6,286	

2) Operating leases

The Group rents buildings and others under operating leases.

Future minimum lease payments under non-cancellable operating leases are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Not later than one year	¥ 4,203	¥ 3,825	¥ 3,543	\$ 37,527
Later than one year and not later than five years	8,000	6,969	6,671	71,429
Later than five years	5,898	5,576	5,944	52,661
Total	¥ 18,103	¥ 16,371	¥ 16,158	\$ 161,634

Minimum lease payments recognized as expenses for the years ended March 31, 2017 and 2016, were ¥5,115 million (\$45,670 thousand) and ¥4,852 million, respectively.

15. PROVISIONS

Reconciliations of provisions from the beginning balances to the ending balances are as follows:

	Millions of Yen			
	Provisions for product warranties	Asset retirement obligations	Liability for special contributions on multi- employer plan	Total
As of April 1, 2015	¥ 450	¥ 124	¥ 2,187	¥ 2,762
Provision made	374		167	542
Increase associated with passage of time		1	10	11
Provision used	(254)	(2)	(146)	(402)
Effects of foreign currency exchange differences	(16)	(0)		(17)
As of March 31, 2016	554	123	2,218	2,896
Provision made	359	101	59	520
Increase associated with passage of time		1	3	5
Provision used	(321)	(1)	(157)	(479)
Effects of foreign currency exchange differences	(13)	(0)		(13)
As of March 31, 2017	¥ 579	¥ 224	¥ 2,124	¥ 2,928

	Thousands of U.S. Dollars			
	Provisions for product warranties	Asset retirement obligations	Liability for special contributions on multi- employer plan	Total
As of March 31, 2016	\$ 4,946	\$ 1,098	\$ 19,804	\$ 25,857
Provision made	3,205	902	527	4,643
Increase associated with passage of time		9	27	45
Provision used	(2,866)	(9)	(1,402)	(4,277)
Effects of foreign currency exchange differences	(116)	(0)		(116)
As of March 31, 2017	\$ 5,170	\$ 2,000	\$ 18,964	\$ 26,143

As a provision for product warranties, the Group recognized the expected service expenses within the warranty period based on historical data. In most cases, the warranty period is one year.

Asset retirement obligations mainly consist of obligations to restore rented buildings and other assets to their original states. While such expenses are expected to be paid after their estimated period of use, they are affected by future business plans and other factors.

For liability for special contributions on multi-employer plan, please refer to "16. POST-EMPLOYMENT BENEFITS."

16. POST-EMPLOYMENT BENEFITS

The Company has a cash balance plan as a defined benefit plan. Under the defined benefit plan, benefits are calculated according to length of service, salary levels, and other factors. The Company or asset managers are required by law to act in the best interests of the plan participants and are responsible for managing the plan assets in accordance with the designated policy. The defined benefit plan is a contract-type pension. The Company operates the plan by entrusting trust banks and other financial institutions to manage payment of contributions and plan assets. Trust banks are contracted by the Company to manage and invest pension assets while engaging in actuarial calculations and operations to pay out annuities and lump-sum payments. Effective April 1, 2015, the Company revised its retirement benefit system and transitioned to a cash balance plan as a defined benefit pension plan, and it has transitioned a portion of its defined benefit pension plan to a defined contribution pension plan. In conjunction with this transition, the Company has recognized prior service costs and gains and losses on settlement in the consolidated statement of income for the year ended March 31, 2016.

The Company and its certain subsidiaries have lump-sum retirement plans and defined contribution pension plans.

Additionally, the Company and certain of its subsidiaries participate in multi-employer plans - the Pension Fund of Japan Electronics Information Technology Industry and the Osaka Pharmaceutical Employees' Pension Fund. While these pension plans are defined benefit plans, sufficient information has not been available to use defined benefit accounting, and consequently, the amounts of contributions have been recognized as retirement benefit expenses, similarly to those of defined contribution plans. In addition, special contributions to such plans are recognized as liabilities discounted to the present value for the portion in which the amount to be borne by the Group has been clarified through actuarial recalculation, while such liabilities are reversed upon payment of special contributions (see "15. PROVISIONS"). The Pension Fund of Japan Electronics Information Technology Industry was approved to return the substitutional portion of future pension obligations to government, effective April 1, 2016.

(1) Defined benefit plan

Amounts recognized in the consolidated statement of financial position arising from the defined benefit plan are as follows:

	Millions of Yen			Thousands of
	March 31, 2017	March 31, 2016	Date of transition to IFRS	U.S. Dollars March 31, 2017
Present value of defined benefit obligation	¥ 8,903	¥ 9,782	¥ 13,161	\$ 79,491
Fair value of plan assets	10,421	9,798	13,559	93,045
Total	¥ (1,518)	¥ (16)	¥ (398)	\$ (13,554)
Effects of asset ceiling	1,506			13,446
Net liability arising from defined benefit plan	¥ (11)	¥ (16)	¥ (398)	\$ (98)
Amount in consolidated statement of financial position				
Liabilities	¥ 654	¥ 566	¥ 562	\$ 5,839
Assets	666	582	960	5,946

Amounts recognized in the consolidated statement of income and consolidated statement of comprehensive income with regard to the defined benefit plan are as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Defined benefit costs recognized in profit or loss			
Current service cost	¥ 828	¥ 724	\$ 7,393
Past service cost		111	
Net interest expense	(3)	(13)	(27)
Changes due to the transition to defined contribution pension plans		(600)	
Subtotal	825	222	7,366
Defined benefit costs recognized in other comprehensive income			
Changes due to the transition to defined contribution pension plans		11	
Remeasurements			
Return on plan assets (excluding amounts included in net interest expense)	(545)	343	(4,866)
Actuarial gains and losses arising from changes in demographic assumptions		52	
Actuarial gains and losses arising from changes in financial assumptions	(1,327)	461	(11,848)
Actuarial gains and losses arising from experience adjustments	165	(62)	1,473
Amount of changes in effects of asset ceiling	1,506	(11)	13,446
Subtotal	(200)	795	(1,786)
Total	¥ 624	¥ 1,018	\$ 5,571

Defined benefit costs recognized in profit or loss are included in "Cost of sales;" "Selling, general and administrative expenses;" and "Research and development expenses" in the consolidated statement of income.

- 1) Reconciliations of the present value of defined benefit obligations from the beginning balance to the ending balance

Reconciliation of the present value of defined benefit obligations is as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Beginning balance	¥ 9,782	¥ 13,161	\$ 87,339
Current service cost	828	724	7,393
Past service cost		111	
Interest expense	53	83	473
Changes due to the transition to defined contribution pension plans		(4,048)	
Remeasurements			
Actuarial gains and losses arising from changes in demographic assumptions		52	
Actuarial gains and losses arising from changes in financial assumptions	(1,327)	461	(11,848)
Actuarial gains and losses arising from experience adjustments	165	(62)	1,473
Benefits paid	(584)	(620)	(5,214)
Effects of foreign currency exchange differences	(15)	(20)	(134)
Other	1	(61)	9
Ending balance	¥ 8,903	¥ 9,782	\$ 79,491

The weighted-average durations of defined benefit obligations as of March 31, 2017, March 31, 2016, and the date of transition to IFRS were 13 years, 13 years, and 12 years, respectively.

2) Reconciliation of the fair value of plan assets from the beginning balance to the ending balance

Reconciliation of the fair value of plan assets is as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Beginning balance	¥ 9,798	¥ 13,559	\$ 87,482
Interest income	56	97	500
Changes due to the transition to defined contribution pension plans		(3,448)	
Remeasurement			
Return on plan assets (excluding amounts included in interest income)	545	(343)	4,866
Contributions from the employer	523	500	4,670
Benefits paid	(503)	(566)	(4,491)
Ending balance	¥ 10,421	¥ 9,798	\$ 93,045

The Company expects ¥523 million (\$4,670 thousand) of the contribution to be paid to the defined benefit plan in the year ending March 31, 2018.

With regard to the defined benefit pension plan, the Group periodically recalculates the amount of contributions in order to maintain a balanced budget into the future.

Investment of the Group's plan assets is conducted within an acceptable range to ensure comprehensive returns over the medium to long term; these are required in order to steadily pay out annuities and lump-sum payments stipulated in the defined benefit pension contracts, and to build up a portfolio of quality plan assets.

To this end, the Group maintains an investment policy of diversified investments after analyzing the attributes of risk and return on each asset and taking into account correlations among particular assets. Specifically, it determines a policy asset mix that efficiently combines various assets, such as stocks and bonds, and seeks to maintain that mix. Furthermore, periodic reviews of the policy asset mix are conducted in an effort to stay abreast of changes in the market environment, which have taken place since the initial assumptions were made, and changes in funding status.

3) Reconciliation of the asset ceiling

Reconciliation of the changes in effects of asset ceiling is as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Beginning balance	¥	¥	\$
Changes due to the transition to defined contribution pension plans		11	
Remeasurement			
Changes in effects of asset ceiling	1,506	(11)	13,446
Ending balance	¥ 1,506	¥	\$ 13,446

4) Fair values of major categories of plan assets

Fair values of major categories of plan assets are as follows:

	Millions of Yen						Date of transition to IFRS		
	March 31, 2017			March 31, 2016					
	Assets with quoted market price in an active market	Assets without quoted market price in an active market	Total	Assets with quoted market price in an active market	Assets without quoted market price in an active market	Total	Assets with quoted market price in an active market	Assets without quoted market price in an active market	Total
Domestic bonds	¥ 3,311		¥ 3,311	¥ 2,865		¥ 2,865	¥ 3,985		¥ 3,985
Domestic equity	2,956		2,956	2,732		2,732	4,118		4,118
Foreign bonds	961		961	1,021		1,021	1,454		1,454
Foreign equity	2,624		2,624	2,409		2,409	3,312		3,312
Others		¥ 568	568		¥ 769	769		¥ 688	688
Total	¥ 9,853	¥ 568	¥10,421	¥ 9,029	¥ 769	¥ 9,798	¥12,871	¥ 688	¥13,559

Thousands of U.S. Dollars			
March 31, 2017			
	Assets with quoted market price in an active market	Assets without quoted market price in an active market	Total
Domestic bonds	\$29,563		\$29,563
Domestic equity	26,393		26,393
Foreign bonds	8,580		8,580
Foreign equity	23,429		23,429
Others		\$ 5,071	5,071
Total	\$87,973	\$ 5,071	\$93,045

5) Actuarial assumptions

Principal actuarial assumptions are as follows:

	March 31, 2017	March 31, 2016	Date of transition to IFRS
Discount rate	0.7%	0.6%	1.0%

6) Sensitivity analysis of actuarial assumptions

If the principal actuarial assumptions change within a reasonable range, the impact on defined benefit obligations will be as shown below. This analysis assumes a situation whereby changes occur in one assumption while all other assumptions remain unchanged.

Assumption	Change in assumption	Millions of Yen			Thousands of U.S. Dollars
		March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Discount rate	Rise by 0.5%	¥ (501)	¥ (593)	¥ (714)	\$ (4,473)
	Decline by 0.5%	552	656	781	4,929

(2) Defined contribution plan

Expenses recognized with respect to the defined contribution plan as of March 31, 2017 and 2016, were ¥3,798 million (\$33,911 thousand) and ¥3,195 million, respectively.

The above expenses are included in "Cost of sales;" "Selling, general and administrative expenses;" and "Research and development expenses."

(3) Multi-employer plans

The funding statuses of contributions to each multi-employer plan based on the latest available materials are as follows:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Pension Fund of Japan Electronics Information Technology Industry				
Plan assets	¥ 256,615	¥ 261,938	¥ 231,950	\$ 2,291,205
Sum of actuarial liabilities of pension plan finance calculation and minimum actuarial reserve	274,553	284,214	262,246	2,451,366
Net balance	(17,937)	(22,275)	(30,295)	(160,152)
Ratio of Group contributions to total plan	5.9%	5.6%	5.3%	5.9%
Osaka Pharmaceutical Employees' Pension Fund				
Plan assets	¥ 306,490	¥ 334,667	¥ 292,416	\$ 2,736,518
Sum of actuarial liabilities of pension plan finance calculation and minimum actuarial reserve	365,488	381,437	366,867	3,263,286
Net balance	(58,997)	(46,769)	(74,450)	(526,759)
Ratio of Group contributions to total plan	0.2%	0.2%	0.2%	0.2%

Notes:

1. The above differences are mainly due to the deficit on the pension plan's statutory balance sheet. The main causes of the deficit are unfounded carryforwards, the difference between book value and fair value of plan assets, and unamortized prior service costs.
2. The contributions are calculated based on a participant's standard salary. The contribution is recalculated at least once every five years in order to maintain the plan balance in accordance with statutory standards.
3. The plan assets may be used as pension benefits for the participants of other company. When an employer ceases to contribute to the plan, other employers may be obligated to it.
4. In the event that the fund dissolves and liquidates, deficit will be collected from employers required by law. When an employer withdraws from the plan, the employer will be obligated to contribute for deficit.
5. The Group has an estimated contribution of ¥273 million (\$2,438 thousand) to the plans for the fiscal year ending March 31, 2018.

17. OTHER FINANCIAL ASSETS AND LIABILITIES

Other short-term financial assets, other long-term financial assets, other short-term financial liabilities, and long-term financial liabilities consist of the following:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Other short-term financial assets				
Bonds	¥ 212	¥ 299	¥ 240	\$ 1,893
Derivative financial assets	71	252	3	634
Others	244	63	53	2,179
Total	¥ 528	¥ 615	¥ 298	\$ 4,714
Other long-term financial assets				
Stocks, etc.	¥ 4,879	¥ 4,914	¥ 5,570	\$ 43,563
Insurance reserve funds	304	297	291	2,714
Others	923	798	578	8,241
Total	¥ 6,107	¥ 6,010	¥ 6,440	\$ 54,527

Bonds, derivative financial assets, and insurance reserve funds are classified into financial assets measured at fair value through profit and loss. Stocks and similar equity instruments are classified into either financial assets measured at fair value through profit and loss or financial assets measured at fair value through other comprehensive income.

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Other short-term financial liabilities				
Deposits received	¥ 462	¥ 492	¥ 495	\$ 4,125
Lease obligations	170	149	49	1,518
Derivative financial liabilities	319	1	54	2,848
Others	4	144	401	36
Total	¥ 956	¥ 788	¥ 1,001	\$ 8,536
Long-term financial liabilities				
Lease obligations	¥ 534	¥ 733	¥ 196	\$ 4,768
Others	15	1	146	134
Total	¥ 549	¥ 734	¥ 342	\$ 4,902

Deposits received and lease obligations are classified into financial liabilities measured at amortized cost. Derivative financial liabilities are classified into financial liabilities measured at fair value through profit or loss.

18. OTHER ASSETS AND LIABILITIES

Other current assets, other non-current assets, other current liabilities, and other non-current liabilities consist of the following:

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Other current assets				
Consumption taxes receivable	¥ 3,015	¥ 3,719	¥ 2,966	\$ 26,920
Prepaid expenses	2,781	2,201	1,996	24,830
Advance payments	577	622	382	5,152
Accrued income	295	381	248	2,634
Others	633	523	891	5,652
Total	¥ 7,303	¥ 7,450	¥ 6,484	\$ 65,205
Other non-current assets				
Guarantee deposits	¥ 1,402	¥ 1,347	¥ 1,288	\$ 12,518
Others	693	581	429	6,188
Total	¥ 2,095	¥ 1,928	¥ 1,717	\$ 18,705

	Millions of Yen			Thousands of U.S. Dollars
	March 31, 2017	March 31, 2016	Date of transition to IFRS	March 31, 2017
Other current liabilities				
Unearned revenue	¥ 5,754	¥ 5,010	¥ 4,814	\$ 51,375
Accrued short-term paid leave	2,210	1,950	1,687	19,732
Accrued directors' bonuses	433	526	411	3,866
Others	1,309	1,895	2,171	11,688
Total	¥ 9,708	¥ 9,383	¥ 9,084	\$ 86,679
Other non-current liabilities				
Lease incentives	¥ 949	¥ 1,064	¥ 1,251	\$ 8,473
Accrued long-term paid leave	262	261	223	2,339
Others	2,315	1,866	1,619	20,670
Total	¥ 3,527	¥ 3,192	¥ 3,094	\$ 31,491

19. EQUITY

(1) Capital stock and capital surplus

Capital surplus comprises amounts generated through capital transactions that were not included in capital stock, and other capital surplus.

Reconciliations of number of authorized shares and number of issued shares from beginning balance to ending balance are as follows:

	Thousands of shares			
	2017		2016	
	Number of authorized shares	Number of issued shares	Number of authorized shares	Number of issued shares
Beginning balance	598,688	208,332	598,688	207,894
Increase/decrease during the period		298		438
Ending balance	598,688	208,631	598,688	208,332

Notes:

1. Shares issued by the Company are common stock with no par value, and outstanding shares are fully paid up.
2. The increase of 298 thousand shares in the number of issued shares in the year ended March 31, 2017, was due to the exercise of subscription rights to shares as stock options.
3. The increase of 438 thousand shares in the number of issued shares in the year ended March 31, 2016, was due to the exercise of subscription rights to shares as stock options.

(2) Treasury stocks

Reconciliation of the number of treasury stocks from beginning balance to ending balance is as follows:

	Thousands of shares	
	2017	2016
Beginning balance	444	443
Increase/decrease during the period	0	0
Ending balance	444	444

Notes:

The increase in the number of treasury stocks in the years ended March 31, 2017 and 2016, were due to purchases of fractional shares less than one unit.

(3) Retained earnings

Retained earnings comprise legal reserve of retained earnings and unappropriated retained earnings.

(4) Other components of equity

- 1) Net gain (loss) on financial assets measured at fair value through other comprehensive income

Amounts consist of changes in fair value of financial assets measured at fair value through other comprehensive income.

- 2) Remeasurements of defined benefit plans

Remeasurements of defined benefit plans consist of actuarial differences, return on plan assets (excluding amounts included in interest income), and changes in effects of asset ceiling (excluding amounts included in interest income). Actuarial differences consist of actual adjustments relating to defined benefit obligations (i.e., the difference between actuarial assumptions at the beginning of period and actual results) and the effects of changes in actuarial assumptions. These amounts are recognized in other comprehensive income when they occur and are immediately reclassified from other components of equity into retained earnings.

3) Exchange difference on translation of foreign operations

Amounts consist of exchange differences arising from consolidation of the financial statements of foreign operations denominated in a currency other than the functional currency of the Company.

Details and amounts of other components of equity are as follows:

	Millions of Yen			
	Net gain (loss) on financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	Exchange difference on translation of foreign operations	Total
As of April 1, 2015	¥ 1,246	¥	¥	¥ 1,246
Other comprehensive income	(430)	(536)	(5,091)	(6,058)
Reclassification into retained earnings		536		536
As of March 31, 2016	815		(5,091)	(4,275)
Other comprehensive income	158	139	(3,607)	(3,309)
Reclassification into retained earnings	(1)	(139)		(141)
As of March 31, 2017	¥ 972	¥	¥ (8,698)	¥ (7,725)

	Thousands of U.S. Dollars			
	Net gain (loss) on financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans	Exchange difference on translation of foreign operations	Total
As of March 31, 2016	\$ 7,277	\$	\$ (45,455)	\$ (38,170)
Other comprehensive income	1,411	1,241	(32,205)	(29,545)
Reclassification into retained earnings	(9)	(1,241)		(1,259)
As of March 31, 2017	\$ 8,679	\$	\$ (77,661)	\$ (68,973)

(5) Dividends

Dividends paid are as follows:

Year Ended March 31, 2017

Resolution	Class of shares	Total dividends (Millions of Yen)	Dividends per share (Yen)	Total dividends (Thousands of U.S. Dollars)	Dividends per share (U.S. Dollars)	Dividend record date	Effective date
Ordinary General Meeting of Shareholders	Common stock	¥5,820	¥28.00	\$51,964	\$0.25	March 31, 2016	June 27, 2016
Board of Directors' Meeting	Common stock	¥5,825	¥28.00	\$52,009	\$0.25	September 30, 2016	December 5, 2016

Year Ended March 31, 2016

Resolution	Class of shares	Total dividends (Millions of Yen)	Dividends per share (Yen)	Dividend record date	Effective date
Ordinary General Meeting of Shareholders June 19, 2015	Common stock	¥4,563	¥22.00	March 31, 2015	June 22, 2015
Board of Directors' Meeting November 5, 2015	Common stock	¥4,985	¥24.00	September 30, 2015	December 2, 2015

Dividends with effective dates in the following fiscal year are as follows:

Year Ended March 31, 2017

Resolution	Class of shares	Total dividends (Millions of Yen)	Dividends per share (Yen)	Total dividends (Thousands of U.S. Dollars)	Dividends per share (U.S. Dollars)	Dividend record date	Effective date
Ordinary General Meeting of Shareholders June 23, 2017	Common stock	¥6,245	¥30.00	\$55,759	\$0.27	March 31, 2017	June 26, 2017

Year Ended March 31, 2016

Resolution	Class of shares	Total dividends (Millions of Yen)	Dividends per share (Yen)	Dividend record date	Effective date
Ordinary General Meeting of Shareholders June 24, 2016	Common stock	¥5,820	¥28.00	March 31, 2016	June 27, 2016

20. INFORMATION OF EXPENSES BY NATURE

Information of expenses by nature is as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Cost of materials	¥ 42,818	¥ 46,301	\$ 382,304
Personnel expenses	67,003	67,860	598,241
Depreciation and amortization	12,381	12,110	110,545

21. OTHER OPERATING INCOME AND EXPENSES

Other operating income and other operating expenses consist of the following:

	Millions of Yen		Thousands of
	2017	2016	U.S. Dollars
Other operating income			2017
Subsidies	¥ 221	¥ 310	\$ 1,973
Gain on sales of property, plant and equipment	50	22	446
Gain on step acquisitions	534		4,768
Others	471	278	4,205
Total	¥ 1,277	¥ 610	\$ 11,402
Other operating expenses			
Loss on sales and retirement of property, plant and equipment	¥ 214	¥ 347	\$ 1,911
Others	182	240	1,625
Total	¥ 397	¥ 588	\$ 3,545

Note:

Subsidies consist of government subsidies received for business activities conducted in special economic areas. There was no unfulfilled conditions or other contingent events entailed by these subsidies.

22. FINANCIAL INCOME AND FINANCIAL EXPENSES

Financial income and financial expenses consist of the following:

	Millions of Yen		Thousands of
	2017	2016	U.S. Dollars
Financial income			2017
Interest income			
Financial assets measured at amortized cost	¥ 188	¥ 252	\$ 1,679
Dividend income			
Financial assets measured at fair value through other comprehensive income	237	82	2,116
Others	88	47	786
Total	¥ 514	¥ 382	\$ 4,589
Financial expenses			
Interest expenses			
Financial liabilities measured at amortized cost	¥ 104	¥ 46	\$ 929
Loss related to stock, etc.			
Financial assets measured at fair value through profit or loss	220	5	1,964
Others	47	44	420
Total	¥ 372	¥ 96	\$ 3,321

23. OTHER COMPREHENSIVE INCOME

Amounts of each item of other comprehensive income for the year, reclassification adjustments to profit or loss, and the impact of tax effects are as follows:

Year Ended March 31, 2017

	Millions of Yen				
	Amount incurred	Reclassification adjustments	Before tax effects	Tax effects	After tax effects
Items that will not be reclassified subsequently to profit or loss					
Net gain (loss) on financial assets measured at fair value through other comprehensive income	¥ 227	¥	¥ 227	¥ (69)	¥ 158
Remeasurements of defined benefit plans	200		200	(61)	139
Subtotal	428		428	(130)	298
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	(3,606)		(3,606)		(3,606)
Share of other comprehensive income of investments accounted for using the equity method	(0)		(0)		(0)
Subtotal	(3,607)		(3,607)		(3,607)
Total	¥ (3,178)	¥	¥ (3,178)	¥ (130)	¥ (3,309)

Year Ended March 31, 2016

	Millions of Yen				
	Amount incurred	Reclassification adjustments	Before tax effects	Tax effects	After tax effects
Items that will not be reclassified subsequently to profit or loss					
Net gain (loss) on financial assets measured at fair value through other comprehensive income	¥ (650)	¥	¥ (650)	¥ 219	¥ (430)
Remeasurements of defined benefit plans	(795)		(795)	259	(536)
Subtotal	(1,446)		(1,446)	479	(967)
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	(5,091)		(5,091)		(5,091)
Share of other comprehensive income of investments accounted for using the equity method					
Subtotal	(5,091)		(5,091)		(5,091)
Total	¥ (6,538)	¥	¥ (6,538)	¥ 479	¥ (6,059)

Year Ended March 31, 2017

	Thousands of U.S. Dollars				
	Amount incurred	Reclassification adjustments	Before tax effects	Tax effects	After tax effects
Items that will not be reclassified subsequently to profit or loss					
Net gain (loss) on financial assets measured at fair value through other comprehensive income	\$ 2,027	\$	\$ 2,027	\$ (616)	\$ 1,411
Remeasurements of defined benefit plans	1,786		1,786	(545)	1,241
Subtotal	3,821		3,821	(1,161)	2,661
Items that may be reclassified subsequently to profit or loss					
Exchange differences on translation of foreign operations	(32,196)		(32,196)		(32,196)
Share of other comprehensive income of investments accounted for using the equity method	(0)		(0)		(0)
Subtotal	(32,205)		(32,205)		(32,205)
Total	\$ (28,375)	\$	\$ (28,375)	\$ (1,161)	\$ (29,545)

24. EARNINGS PER SHARE

The basis for calculating basic and diluted earnings per share is as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Basis for calculating basic earnings per share			
Profit attributable to owners of the parent	¥ 40,636	¥ 39,278	\$ 362,821
Profit not attributable to common stock shareholders of the parent			
Profit used in calculating basic earnings per share	40,636	39,278	362,821
Average number of common stock shares during the period (Thousands of shares)	208,058	207,734	208,058
Basis for calculating diluted earnings per share			
Profit used in calculating basic earnings per share	40,636	39,278	362,821
Profit adjustment			
Profit used in calculating diluted earnings per share	40,636	39,278	362,821
Average number of common stock shares during the period (Thousands of shares)	208,058	207,734	208,058
Effect of dilutive shares (Thousands of shares)	609	856	609
Average number of common stock shares after adjustment for dilution (Thousands of shares)	208,667	208,590	208,667

25. NON-CASH TRANSACTIONS

Non-cash transactions during the year ended March 31, 2016, consist of the acquisition of non-current assets through new finance lease arrangements in the amount of ¥708 million.

26. STOCK-BASED COMPENSATION

(1) Details of stock-based compensation

The Company has adopted a stock option plan for members of the Managing Board, executive officers and employees, and members of the Managing Board and employees of some of its subsidiaries.

The details are as follows:

Grant date	September 13, 2013
Number and type of shares	Common stock 1,460 thousand shares
Exercise period	Within six years from vesting, provided, however, that those who retire after vesting may exercise their rights for only two years from retirement date
Exercise price	¥3,110
Settlement method	Equity settled
Exercise conditions	Must be employed by the Company continuously from the grant date (September 31, 2013) through the vesting date (September 12, 2015)

(2) The number of stock options and the weighted-average exercise prices

	2017		2016		2017	
	Number of shares (Thousand shares)	Weighted-average exercise price (Yen)	Number of shares (Thousand shares)	Weighted-average exercise price (Yen)	Number of shares (Thousand shares)	Weighted-average exercise price (U.S. Dollars)
Outstanding at beginning of period	1,255	¥ 3,110	1,438	¥ 3,110	1,255	\$ 27,768
Forfeited during period	(0)	3,110	(8)	3,110	(0)	27,768
Exercised during period	(298)	3,110	(174)	3,110	(298)	27,768
Outstanding at end of period	956	¥ 3,110	1,255	¥ 3,110	956	\$ 27,768
Exercisable at end of period	956	¥ 3,110	1,255	¥ 3,110	956	\$ 27,768

Notes:

1. The weighted-average share price on the exercise date for the years ended March 31, 2017 and 2016, was ¥7,080 (\$63,214) and ¥7,178, respectively.
2. The exercise price of outstanding stock options for the years ended March 31, 2017 and 2016, was ¥3,110 (\$27,768) and ¥3,110, respectively.
3. The weighted-average remaining contractual life for the years ended March 31, 2017 and 2016, were four years and five years.

(3) Stock-based compensation transactions to which IFRS 2 "Share-Based Payment" has not been applied

Due to the exemption provision of IFRS 1, IFRS 2 "Share-Based Payment" has not been applied to the following stock option as it was granted after November 7, 2002, but was vested prior to the date of transition to IFRS:

Grant date	July 30, 2007
Number and type of shares	Common stock 2,932 thousand shares
Exercise period	Within six years from vesting; provided, however, that those who retire after vesting may exercise their rights for only two years from retirement date.
Exercise price	¥1,163
Settlement method	Equity-settled
Exercise conditions	Must be employed by the Company continuously from the grant date (July 30, 2007) through the vesting date (July 29, 2009).

The number of exercisable shares and the average exercise prices are as follows:

	2017		2016		2017	
	Number of shares (Thousand shares)	Weighted-average exercise price (Yen)	Number of shares (Thousand shares)	Weighted-average exercise price (Yen)	Number of shares (Thousand shares)	Weighted-average exercise price (U.S. Dollars)
Outstanding at beginning of period		¥	336	¥ 1,163		\$
Forfeited during period			(10)	1,163		
Exercised during period			(263)	1,163		
Expired during period			(63)	1,163		
Outstanding at end of period		¥		¥		\$
Exercisable at end of period		¥		¥		\$

(4) Expenses associated with stock-based compensation transactions

Expenses associated with stock-based compensation transactions in the year ended March 31, 2016, was ¥312 million. Such expenses are included in "Cost of sales," "Selling, general and administrative expenses," and "Research and development expenses" in the consolidated statement of income.

27. FINANCIAL INSTRUMENTS

(1) Capital management

The Group, in an effort to maximize its corporate value through sustained growth, has been focusing on capital management to maintain financial soundness in preparation for business investments that ensure growth, while enhancing capital efficiency.

To this end, the Group periodically monitors its ROE (ratio of profit attributable to owners of the parent to average equity attributable to the owners of the parent) to gauge its capital efficiency and its equity ratio (ratio of equity attributable to the owners of the parent) for its financial soundness. ROE for the years ended March 31, 2017, and March 31, 2016, were 20.7% and 23.1%, respectively, and the equity ratio for the years ended March 31, 2017, and March 31, 2016, and at the date of transition to IFRS and were 74.8%, 69.3%, and 66.6%, respectively. The equity ratio was calculated by dividing total equity attributable to the owners of the parent by total liabilities and equity.

The Company, as part of efforts to expeditiously raise funds, has acquired an issuer rating of A+ (Single A plus) from Rating and Investment Information, Inc. (R&I), and updates such ratings through yearly reviews. Maintaining and improving such ratings contribute to keeping down future funding costs.

The Group is not subject to any material capital restrictions.

(2) Financial risk management policy

In the course of executing business activities, the Group is exposed to various financial risks (credit, liquidity, and market). In order to avoid or mitigate such risks, the Group engages in risk management based on certain policies.

The Group invests funds in low-risk financial assets, mainly short-term deposits, and uses financial instruments, mainly bank loans, for funding.

Derivative transactions have been approved by a predetermined decision-maker based on the internal guidelines, which prescribe the authority and the limit, and are managed through the finance department regularly confirming the balance as at each due date.

(3) Credit risk management

The Company manages its credit risk from receivables on the basis of internal guidelines, which include monitoring of payment terms and balances for major customers by each business administration department in order to identify at an early stage any customer default risks due to deteriorating finances. The credit risk regarding subsidiaries is also managed in the same manner.

Credit risk from derivatives is minimized due to dealing only with large financial institutions.

The carrying amounts of financial assets after impairment loss stated in the consolidated statement of financial position represent the maximum exposure to credit risk at reporting dates that do not take into account collateral and other credit enhancements. The counterparties and trading areas of the Group are extensive, and no significant concentration of the credit risk has occurred.

The Group calculates the loss allowance by classifying them into the categories of trade and lease receivables, and non-trade and non-lease receivables. Both types of financial assets are treated as defaults at the point when contracted payment terms and conditions cannot be met.

The Group recognizes loss allowance for all trade and lease receivables at an amount equal to the lifetime expected credit loss. Loss allowance is calculated to reflect the following factors:

- (a) Unbiased, probability-weighted amounts derived by evaluating the probable results within a certain range;
- (b) Time value of money;
- (c) Reasonable and supportable information that is available without undue cost or effort at the reporting date, about past events, current conditions, and future economic conditions.

For both types of financial assets, when evaluating whether or not the credit risk has increased significantly, in addition to information on due dates, the Group considers information that can be reasonably used and supported by the Group. Both types of financial assets are treated as credit-impaired financial assets in the event that the borrower requests revision of the payment terms and conditions, the borrower falls into serious financial difficulty, or legal liquidation procedures commence due to the borrower's bankruptcy, etc. In terms of amounts that are clearly not capable of being collected in future periods, the carrying amounts of financial assets are directly reduced and the corresponding loss allowance is also decreased.

Changes in the loss allowance are as follows:

	Millions of Yen			
	Financial assets with loss allowance measured at an amount equal to 12-month expected credit loss	Financial assets with loss allowance measured at an amount equal to lifetime expected credit loss		Total
	Credit-impaired financial assets	Trade and lease receivables		
As of April 1, 2015	¥ 3	¥ 0	¥ 574	¥ 579
Provision made			262	262
Provision used			(101)	(101)
Provision reversed	(2)		(108)	(110)
Exchange differences on translation of foreign currency	(0)	(0)	(37)	(37)
As of March 31, 2016	1	0	590	592
Provision made			244	244
Provision used			(103)	(103)
Provision reversed			(110)	(110)
Exchange differences on translation of foreign currency	(0)	(0)	(37)	(37)
As of March 31, 2017	¥ 1	¥ 0	¥ 583	¥ 585

	Thousands of U.S. Dollars			
	Financial assets with loss allowance measured at an amount equal to lifetime expected credit loss			
	Financial assets with loss allowance measured at an amount equal to 12- month expected credit loss	Credit-impaired financial assets	Trade and lease receivables	Total
As of March 31, 2016	\$ 9	\$ 0	\$ 5,268	\$ 5,286
Provision made			2,179	2,179
Provision used			(920)	(920)
Provision reversed			(982)	(982)
Exchange differences on translation of foreign currency	(0)	(0)	(330)	(330)
As of March 31, 2017	\$ 9	\$ 0	\$ 5,205	\$ 5,223

Note:

There are no financial assets for which credit risk is significantly increasing for the whole period, except for trade and lease receivables.

Changes in the gross-carrying amount of financial assets are as follows:

	Millions of Yen			
	Financial assets with loss allowance measured at an amount equal to lifetime expected credit loss			
	Financial assets with loss allowance measured at an amount equal to 12- month expected credit loss	Credit-impaired financial assets	Trade and lease receivables	Total
As of April 1, 2015	¥ 363	¥ 0	¥ 57,786	¥ 58,150
Recognition and derecognition	358		9,456	9,815
Exchange differences on translation of foreign currency	(36)	(0)	(3,201)	(3,237)
As of March 31, 2016	686	0	64,041	64,728
Recognition and derecognition	(272)		9,829	9,556
Exchange differences on translation of foreign currency	(28)	(0)	(1,767)	(1,795)
As of March 31, 2017	¥ 385	¥ 0	¥ 72,103	¥ 72,489

	Thousands of U.S. Dollars			
	Financial assets with loss allowance measured at an amount equal to 12-month expected credit loss	Credit-impaired financial assets	Trade and lease receivables	Total
As of March 31, 2016	\$ 6,125	\$ 0	\$ 571,795	\$ 577,929
Recognition and derecognition	(2,429)		87,759	85,321
Exchange differences on translation of foreign currency	(250)	(0)	(15,777)	(16,027)
As of March 31, 2017	\$ 3,438	\$ 0	\$ 643,777	\$ 647,223

Note:

There are no financial assets for which credit risk is significantly increasing for the whole period, except for trade and lease receivables.

No financial assets for which loss allowance was recorded at initial recognition were recognized for the years ended March 31, 2017 and 2016.

The carrying amounts of financial assets for which loss allowance was recognized are as follows:

As of March 31, 2017

	Millions of Yen		Thousands of U.S. Dollars	
	Receivable	Loss allowance	Receivable	Loss allowance
Financial assets with significantly increased credit risk or credit-impaired financial assets	¥ 2,514	¥ 493	\$ 22,446	\$ 4,402
Financial assets other than the above	69,974	92	624,768	821
Total	¥ 72,489	¥ 585	\$ 647,223	\$ 5,223

As of March 31, 2016

	Millions of Yen	
	Receivable	Loss allowance
Financial assets with significantly increased credit risk or credit-impaired financial assets	¥ 2,667	¥ 483
Financial assets other than the above	62,061	109
Total	¥ 64,728	¥ 592

Date of transition to IFRS

	Millions of Yen	
	Receivable	Loss allowance
Financial assets with significantly increased credit risk or credit-impaired financial assets	¥ 1,376	¥ 543
Financial assets other than the above	56,774	35
Total	¥ 58,150	¥ 579

(4) Liquidity risk management

The Company manages its liquidity risk by holding adequate volumes of cash on hand in view of business income and expenditure, and capital investment plan along with adequate cash management plan by the finance department. The finance department of the Company manages liquidity risk by obtaining information on cash flows for the whole Group.

The contractual maturities of financial liabilities are as follows:

As of March 31, 2017

	Millions of Yen							
	Carrying amount	Contractual cash flows	Within 1 year	More than 1 year to 2 years	More than 2 years to 3 years	More than 3 years to 4 years	More than 4 years to 5 years	More than 5 years
Non-derivative financial liabilities								
Trade and other payables	¥ 24,376	¥ 24,376	¥ 24,376					
Lease obligations	704	842	230	¥ 225	¥ 209	¥ 130	¥ 23	22
Deposits received	462	462	462					
Others	19	21	4	5	4	5	1	
Subtotal	25,563	25,702	25,074	230	214	135	24	22
Derivative financial liabilities								
Forward exchange contracts	319	319	319					
Subtotal	319	319	319					
Total	¥ 25,882	¥ 26,021	¥ 25,393	¥ 230	¥ 214	¥ 135	¥ 24	22

As of March 31, 2016

	Millions of Yen							
	Carrying amount	Contractual cash flows	Within 1 year	More than 1 year to 2 years	More than 2 years to 3 years	More than 3 years to 4 years	More than 4 years to 5 years	More than 5 years
Non-derivative financial liabilities								
Trade and other payables	¥ 26,824	¥ 26,824	¥ 26,824					
Lease obligations	883	1,105	236	¥ 231	¥ 227	¥ 215	¥ 145	49
Deposits received	492	492	492					
Others	145	145	144	1				
Subtotal	28,345	28,568	27,698	233	227	215	145	49
Derivative financial liabilities								
Forward exchange contracts	1	1	1					
Subtotal	1	1	1					
Total	¥ 28,347	¥ 28,570	¥ 27,699	¥ 233	¥ 227	¥ 215	¥ 145	49

Date of transition to IFRS

	Millions of Yen							
	Carrying amount	Contractual cash flows	Within 1 year	More than 1 year to 2 years	More than 2 years to 3 years	More than 3 years to 4 years	More than 4 years to 5 years	More than 5 years
Non-derivative financial liabilities								
Trade and other payables	¥ 22,776	¥ 22,776	¥ 22,776					
Lease obligations	245	299	60	¥ 44	¥ 41	¥ 38	¥ 28	85
Deposits received	495	495	495					
Others	547	547	401	146				
Subtotal	24,066	24,119	23,734	191	41	38	28	85
Derivative financial liabilities								
Forward exchange contracts	54	54	54					
Subtotal	54	54	54					
Total	¥ 24,120	¥ 24,173	¥ 23,788	¥ 191	¥ 41	¥ 38	¥ 28	85

As of March 31, 2017

	Thousands of U.S. Dollars							
	Carrying amount	Contractual cash flows	Within 1 year	More than 1 year to 2 years	More than 2 years to 3 years	More than 3 years to 4 years	More than 4 years to 5 years	More than 5 years
Non-derivative financial liabilities								
Trade and other payables	\$217,643	\$217,643	\$217,643					
Lease obligations	6,286	7,518	2,054	\$ 2,009	\$ 1,866	\$ 1,161	\$ 205	\$ 196
Deposits received	4,125	4,125	4,125					
Others	170	188	36	45	36	45	9	
Subtotal	228,241	229,482	223,875	2,054	1,911	1,205	214	196
Derivative financial liabilities								
Forward exchange contracts								
	2,848	2,848	2,848					
Subtotal	2,848	2,848	2,848					
Total	\$231,089	\$232,330	\$226,723	\$ 2,054	\$ 1,911	\$ 1,205	\$ 214	\$ 196

Average interest rates as of March 31, 2017, were 9.6% for lease obligations and 0.0% for deposits received.

(5) Market risk management

1) Management of foreign currency exchange rate risk

In terms of foreign currency receivables, foreign currency exchange rate risk, which is summarized with respect to each currency and each month, is managed mainly through use of forward exchange contracts. Forward exchange contracts are used for foreign currency forecast transactions, according to conditions in respect of foreign currency exchange rate fluctuations.

(i) Exposure to foreign currency exchange rate risk

The Group's exposure to foreign currency exchange rate risk is as shown below. The exposure amounts represent the exposure to risk less the foreign currency exchange risks hedged by the forward exchange contracts.

	2017	2016
Thousands of U.S. dollars	15,431	13,538
Thousands of euros	20,406	59,422
Thousands of yuan	(15,110)	(10,286)

(ii) Sensitivity analysis of foreign currency exchange risk

The following shows the impacts on profit and equity of a 10% appreciation of the Japanese yen against the U.S. dollar, euro and yuan. This analysis assumes that all other factors are constant. The impacts of fluctuations in currencies other than the U.S. dollar, euro and yuan on the Group's exposure are immaterial.

	Millions of Yen				Thousands of U.S. Dollars	
	2017		2016		2017	
	Profit	Equity	Profit	Equity	Profit or loss	Equity
U.S. dollar (yen appreciates by 10%)	¥ (119)	¥ (119)	¥ (103)	¥ (103)	\$ (1,063)	\$ (1,063)
Euro (yen appreciates by 10%)	(168)	(168)	(507)	(507)	(1,500)	(1,500)
Yuan (yen appreciates by 10%)	10	10	11	11	89	89

2) Management of interest rate risk

As the Group does not have material financial instruments exposed to interest rate risk, the interest rate risk is limited.

3) Management of market price fluctuation risk

Equity Instruments are managed through regular monitoring of market values and the financial positions of issuers.

With regard to listed shares held by the Group, the impacts of a 10% decline in share prices for the years ended March 31, 2017, and March 31, 2016 and, on the date of transition to IFRS, were ¥349 million (\$3,116 thousand), ¥326 million, and ¥359 million, respectively. This analysis assumes that all other factors are constant.

(6) Fair value of financial instruments

1) Fair value measurement method

The fair values of major financial assets and financial liabilities are determined in the following manner. In measuring the fair values of financial instruments, the quoted price is used, if available. If a quoted price is not available, the method of discounting future cash flows or other appropriate methods are used.

(i) Trade and other receivables

The fair values of lease receivables are measured at the present value calculated by discounting future cash flow, using the applicable discount rate considering credit risk, and classified in Level 3.

(ii) Other financial assets

• Stocks

The fair values of listed stocks are measured from the quoted prices of identical assets in active markets, and classified in Level 1.

The fair values of unlisted stocks are measured, in accordance with the valuation policy and procedures set forth by the Company, using a valuation model based on the net assets of the investee and other appropriate valuation methods, and classified in Level 3.

• Insurance reserve funds

The fair values of insurance reserve funds are measured at the cash surrender value, as there are no significant contractual restrictions on refunds, and classified in Level 3.

(iii) Other financial liabilities

The fair values of lease obligations are measured at the present value, calculated by discounting future cash flows of the total amount of principal and interest, using the interest rate that would presumably apply if a new and similar lease transaction were made, and classified in Level 3.

(iv) Derivative financial assets and derivative financial liabilities

The fair values of forward exchange contracts, etc., are measured based on the prices indicated by the financial institutions, which are the counterparties of the contracts, and classified in Level 2.

The fair values of financial assets and financial liabilities other than those stated above approximate their carrying amounts.

2) Financial instruments measured at amortized cost

The fair values of financial instruments measured at amortized cost are as follows:

	Millions of Yen						Thousands of U.S. Dollars	
	March 31, 2017		March 31, 2016		Date of transition to IFRS		March 31, 2017	
	Carrying amount	Fair value	Carrying amount	Fair value	Carrying amount	Fair value	Carrying amount	Fair value
Assets								
Lease receivables	¥ 11,486	¥ 11,441	¥ 8,535	¥ 8,458	¥ 5,413	¥ 5,365	\$ 102,554	\$ 102,152
Total	11,486	11,441	8,535	8,458	5,413	5,365	102,554	102,152
Liabilities								
Lease obligations	704	683	883	867	245	260	6,286	6,098
Total	¥ 704	¥ 683	¥ 883	¥ 867	¥ 245	¥ 260	\$ 6,286	\$ 6,098

3) Financial instruments measured at fair value

The fair value hierarchy of financial instruments measured at fair value is as follows:

As of March 31, 2017

	Millions of Yen			Total
	Level 1	Level 2	Level 3	
Assets				
Stocks, etc.				
Financial assets measured at fair value through profit or loss			¥ 299	¥ 299
Financial assets measured at fair value through other comprehensive income	¥ 3,496		1,082	4,579
Insurance reserve funds				
Financial assets measured at fair value through profit or loss			304	304
Derivative financial assets				
Financial assets measured at fair value through profit or loss		¥ 71		71
Others				
Financial assets measured at fair value through profit or loss	654	212	262	1,129
Total	¥ 4,151	¥ 284	¥ 1,949	¥ 6,384
Liabilities				
Derivative financial liabilities				
Financial liabilities measured at fair value through profit or loss		¥ 319		¥ 319
Others				
Financial liabilities measured at fair value through profit or loss				
Total		¥ 319		¥ 319

As of March 31, 2016

	Millions of Yen			Total
	Level 1	Level 2	Level 3	
Assets				
Stocks, etc.				
Financial assets measured at fair value through profit or loss			¥ 518	¥ 518
Financial assets measured at fair value through other comprehensive income	¥ 3,264		1,131	4,395
Insurance reserve funds				
Financial assets measured at fair value through profit or loss			297	297
Derivative financial assets				
Financial assets measured at fair value through profit or loss		¥ 252		252
Others				
Financial assets measured at fair value through profit or loss	516	299	262	1,079
Total	¥ 3,780	¥ 551	¥ 2,210	¥ 6,543
Liabilities				
Derivative financial liabilities				
Financial liabilities measured at fair value through profit or loss		¥ 1		¥ 1
Others				
Financial liabilities measured at fair value through profit or loss			¥ 143	143
Total		¥ 1	¥ 143	¥ 145

Date of transition to IFRS

	Millions of Yen			
	Level 1	Level 2	Level 3	Total
Assets				
Stocks, etc.				
Financial assets measured at fair value through profit or loss			¥ 516	¥ 516
Financial assets measured at fair value through other comprehensive income	¥ 3,594		1,459	5,054
Insurance reserve funds				
Financial assets measured at fair value through profit or loss			291	291
Derivative financial assets				
Financial assets measured at fair value through profit or loss		¥ 3		3
Others				
Financial assets measured at fair value through profit or loss	469	240	71	781
Total	¥ 4,063	¥ 244	¥ 2,338	¥ 6,646
Liabilities				
Derivative financial liabilities				
Financial liabilities measured at fair value through profit or loss		¥ 54		¥ 54
Others				
Financial liabilities measured at fair value through profit or loss			¥ 547	547
Total		¥ 54	¥ 547	¥ 602

As of March 31, 2017

	Thousands of U.S. Dollars			
	Level 1	Level 2	Level 3	Total
Assets				
Stocks, etc.				
Financial assets measured at fair value through profit or loss			\$ 2,670	\$ 2,670
Financial assets measured at fair value through other comprehensive income	\$ 31,214		9,661	40,884
Insurance reserve funds				
Financial assets measured at fair value through profit or loss			2,714	2,714
Derivative financial assets				
Financial assets measured at fair value through profit or loss		\$ 634		634
Others				
Financial assets measured at fair value through profit or loss	5,839	1,893	2,339	10,080
Total	\$ 37,063	\$ 2,536	\$ 17,402	\$ 57,000
Liabilities				
Derivative financial liabilities				
Financial liabilities measured at fair value through profit or loss		\$ 2,848		\$ 2,848
Others				
Financial liabilities measured at fair value through profit or loss				
Total		\$ 2,848		\$ 2,848

Note:

Transfers between levels of the fair value hierarchy are recognized on the date on which the event occurred or the situation changed to necessitate the transfer. No transfers occurred in the years ended March 31, 2017, and March 31, 2016.

Increases/decreases in financial assets classified in Level 3 of the fair value hierarchy are as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Beginning balance	¥ 2,210	¥ 2,338	\$ 19,732
Total gains or losses recognized			
In profit or loss (Note 1)	(168)	2	(1,500)
In other comprehensive income (Note 2)	(43)	(330)	(384)
Purchase	13	204	116
Sales or settlement	(5)	(1)	(45)
Others	(56)	(3)	(500)
Ending balance	¥ 1,949	¥ 2,210	\$ 17,402

Increases/decreases in financial liabilities classified in Level 3 of the fair value hierarchy are as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Beginning balance	¥ 143	¥ 547	\$ 1,277
Total gains or losses recognized			
In profit or loss (Note 1)	(3)	(7)	(27)
In other comprehensive income (Note 2)		6	
Sales or settlement	(140)	(403)	(1,250)
Ending balance	¥	¥ 143	\$

Notes:

- Total gains or losses recognized in profit or loss relate to financial assets and financial liabilities measured at fair value through profit or loss, and are included in "Financial income" and "Financial expenses" on consolidated statement of income.
- Total gains or losses recognized in other comprehensive income relate to financial assets and financial liabilities measured at fair value through other comprehensive income, and are included in "Net gain (loss) on financial assets measured at fair value through other comprehensive income" on consolidated statement of comprehensive income.

(7) Financial assets measured at fair value through other comprehensive income

The Group has designated investments in equity instruments held by the Group over the long term for the purpose of generating profit from rises in share prices or dividends, and for the purpose of reinforcing and stabilizing its business base, as financial assets measured at fair value through other comprehensive income.

1) Fair values of each investments

Name of major investments and their fair values are as follows:

As of March 31, 2017

Investment	Millions of Yen	Thousands of U.S. Dollars
TOA Corporation	¥ 1,407	\$ 12,563
Noritz Corporation	992	8,857
Mitsubishi UFJ Financial Group, Inc.	229	2,045
Human Metabolome Technologies, Inc.	153	1,366
Nomura Holdings, Inc.	138	1,232

As of March 31, 2016

Investment	Millions of Yen
TOA Corporation	¥ 1,560
Noritz Corporation	861
Mitsubishi UFJ Financial Group, Inc.	170
Falco Holdings Co., Ltd.	121
Nomura Holdings, Inc.	100

Date of transition to IFRS

Investment	Millions of Yen
TOA Corporation	¥ 1,688
Noritz Corporation	926
Mitsubishi UFJ Financial Group, Inc.	243
Nomura Holdings, Inc.	141
Falco Holdings Co., Ltd.	123

2) Derecognition of financial assets measured at fair value through other comprehensive income

The Group derecognized certain financial assets measured at fair value through other comprehensive income, which were disposed of by way of sales, etc., based on the statuses of market prices, business necessity, and other factors.

Fair values and cumulative gains or losses at the time of disposal are as follows:

Millions of Yen				Thousands of U.S. Dollars	
2017		2016		2017	
Fair value	Cumulative gain or loss	Fair value	Cumulative gain or loss	Fair value	Cumulative gain or loss
¥ 21	¥ 1	¥	¥	\$ 188	\$ 9

3) Dividend income

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Investments held at end of period	¥ 237	¥ 82	\$ 2,116

28. BUSINESS COMBINATIONS

Year ended March 31, 2017

(Acquisition of shares of RIKEN GENESIS CO., LTD.)

(1) Overview of acquired company

Name: RIKEN GENESIS CO., LTD.

Business description: Contracted gene analysis business and diagnostic reagent business

(2) Overview of business combination

The Company acquired additional shares of RIKEN GENESIS CO., LTD. ("Riken Genesis"), which provides contract genetic analysis services and products, and has technology, experience, and expertise in the field of personalized medicine from TOPPAN PRINTING CO., LTD. (Ownership of voting rights: 28.2%). As a result, the Company holds majority ownership of Riken Genesis (Ownership of voting rights: 64.7%), and it converted Riken Genesis and BNA Inc., its subsidiary, into subsidiaries of the Company from the first quarter of the fiscal year ended March 31, 2017. The acquisition was carried out in order to strengthen the synergy between the Group and Riken Genesis, and to accelerate the Company's initiatives toward realization of personalized medicine.

(3) Acquisition date

May 13, 2016

(4) Consideration for acquisition

	Millions of Yen	Thousands of U.S. Dollars
Cash and cash equivalents	¥ 1,540	\$ 13,750
The acquisition-date fair value of the Company's previously held equity interest in Riken Genesis	1,999	17,848
Total	¥ 3,540	\$ 31,607

(5) Acquisition-related costs

The ¥0 million (\$0 thousand) in acquisition-related costs was included in "Selling, general and administrative expenses" in the consolidated statement of income.

(6) Gain on step acquisition

The Company recognized a gain on step acquisition of ¥534 million (\$4,768 thousand) as a result of remeasuring the fair value of the equity interest of 36.5% in Riken Genesis, which the Company previously held on the acquisition date. This gain was included in "Other operating income" in the consolidated statement of income.

(7) Cash flows associated with acquisition

	Millions of Yen	Thousands of U.S. Dollars
Cash and cash equivalents paid due to the acquisition	¥ 1,540	\$ 13,750
Cash and cash equivalents held by the acquired company at the time of acquisition	(227)	(2,027)
Total	¥ 1,312	\$ 11,714

(8) Fair values of assets acquired and liabilities assumed as of the acquisition date

	Millions of Yen	Thousands of U.S. Dollars
Fair values of assets acquired and liabilities assumed		
Current assets	¥ 2,809	\$ 25,080
Cash and cash equivalents	227	2,027
Trade and other receivables (Note 2)	416	3,714
Inventories	156	1,393
Loans receivables (Note 2)	1,930	17,232
Others	77	688
Non-current assets	1,048	9,357
Property, plant and equipment	220	1,964
Intangible assets (Note 1)	821	7,330
Others	6	54
Current liabilities	685	6,116
Trade and other payables	390	3,482
Others	295	2,634
Non-current liabilities	258	2,304
Provisions	11	98
Deferred tax liabilities (Note 1)	246	2,196
Others	1	9
Fair values of assets acquired and liabilities assumed (net)	2,914	26,018
Non-controlling interests (Notes 1 and 3)	1,028	9,179
Goodwill (Notes 1 and 4)	¥ 1,655	\$ 14,777

Notes:

- Acquisition costs have been allocated to assets acquired and liabilities assumed based on the fair values as of the acquisition date. Allocation of acquisition costs was complete as of the end of the second quarter of the fiscal year ended March 31, 2017. Major adjustments to the provisional amounts were as follows:

Intangible assets	Increase of ¥629 million (\$5,616 thousand)
Deferred tax liabilities	Increase of ¥246 million (\$2,196 thousand)

As a result, non-controlling interests increased by ¥92 million (\$821 thousand) and goodwill decreased by ¥290 million (\$2,589 thousand).

- Gross contractual amounts receivable and the best estimate at the acquisition date of the contractual cash flows not expected to be collected are as follows:

	Millions of Yen		Thousands of U.S. Dollars	
	Gross contractual amounts receivables	The best estimate at the acquisition date of the contractual cash flows not expected to be collected	Gross contractual amounts receivables	The best estimate at the acquisition date of the contractual cash flows not expected to be collected
Trade and other receivables	¥ 416	¥ (0)	\$ 3,714	\$ (0)
Loans receivable	1,930		17,232	

3. Non-controlling interests are measured at the proportionate share in the recognized amount of the identifiable net assets.
4. Goodwill reflects excess future earning capacity anticipated as a result of business development and the synergy generated between the Group and the acquired company.

(9) Impact on business results

Due to the immateriality of its impact on the consolidated financial statements, disclosure has been omitted for the impacts of the business combination on net sales and profit included in the consolidated statement of income for the current fiscal year and the impacts on net sales and profit assuming that the business combination had occurred at the beginning of the current fiscal year.

Business combinations occurred after the end of the reporting period, but before the consolidated financial statements were authorized for issuance, as follows:

(Business Transfer from SANTUNG INSTRUMENTS CO., LTD.)

(1) Overview of the business transfer

Name: SANTUNG INSTRUMENTS CO., LTD.

Business description: Sales, service, and support of in vitro diagnostic products

(2) Overview of business combination

A subsidiary, Sysmex Taiwan Co., Ltd., acquired the business of SANTUNG INSTRUMENTS CO., LTD., a distributor in Taiwan. Sysmex Taiwan Co., Ltd., aims to build a sales and service network in Taiwan, to offer the immunochemistry and other new business fields, in addition to hematology, and to expand its business in Taiwan.

(3) Acquisition date

May 2, 2017

(4) Consideration for acquisition

Approximately 1,133 million TWD

As there is a contingent consideration term in the business transfer agreement, the amount may change.

(5) Fair value of assets acquired and liability assumed as of the acquisition date

As the value of the acquisition is under assessment, fair value of assets acquired and liability assumed as of the acquisition date is omitted. The allocation of acquisition costs is also not completed, and the amount of goodwill has not yet been determined.

(Acquisition of shares of Oxford Gene Technology IP Limited)

(1) Overview of the acquired company

Name: Oxford Gene Technology IP Limited

Business description: Development, production, and sale of diagnostic and research reagents used in cytogenetic testing¹ and the development, production, and sale of research reagents used in NGSs².

Notes:

1. Cytogenetic testing:

Cytogenetic testing refers to the study of chromosomes, particularly research related to illnesses arising due to chromosomal abnormalities. Research and testing typically involves the use of white blood cells, amniotic fluid, or tissues samples.

2. Next-generation sequencer (NGS):

An analyzer capable of simultaneously reading the large quantities of DNA basis and sequences that contain genetic information.

(2) Overview of business combination

The Company have acquired all shares of Oxford Gene Technology IP Limited ("OGT"). As a result, OGT and its subsidiaries become consolidated subsidiaries of the Company from the first quarter of the fiscal year ending March 31, 2018. The acquisition was carried out in order to obtain OGT's business and expertise in the cytogenetics domain and its reagent development capabilities used in next-generation sequencers (NGSs), thereby reinforcing its base in the life science business.

(3) Acquisition date

June 8, 2017

(4) Consideration for acquisition

Around 53 million GBP

(5) Fair value of acquired assets and assumption of liability at the reporting date

As it is under assessment, fair value of acquired assets and assumed liabilities at the reporting date is omitted. Since the allocation of acquisition costs has also not been completed, the amount of goodwill and other assets and liabilities are not determined.

29. RELATED PARTIES

(1) Related party transaction

The Group engages in transactions with the following related parties:

Transactions with subsidiaries, which are related parties of the Company, have been eliminated in consolidation and are therefore not disclosed.

As of March 31, 2017

Type	Name	Nature of transaction with related parties	Transaction amount		Outstanding	
			Millions of Yen	Thousands of U.S. Dollars	Millions of Yen	Thousands of U.S. Dollars
Officer	Masayoshi Hayashi	Exercise of stock options	¥ 93	\$ 830	¥	\$
Officer	Yukio Nakajima	Exercise of stock options	31	277		
Officer	Koji Tamura	Exercise of stock options	23	205		
Officer	Mitsuru Watanabe	Exercise of stock options	23	205		
Officer	Kazuya Obe	Exercise of stock options	11	98		
Officer	Kaoru Asano	Exercise of stock options	11	98		
Officer	Kenji Tachibana	Exercise of stock options	11	98		

As of March 31, 2016

Type	Name	Nature of transaction with related parties	Transaction amount (Millions of Yen)		Outstanding (Millions of Yen)
Officer	Hisashi Ietsugu	Exercise of stock options	¥	93	¥
Officer	Masayoshi Hayashi	Exercise of stock options		31	
Officer	Kazuya Obe	Exercise of stock options		11	
Officer	Mitsuru Watanabe	Exercise of stock options		11	

Note:

The exercise price of stock options and other matters relating to stock options are as disclosed in "26. STOCK-BASED COMPENSATION."

(2) Key management personnel compensation

Key management personnel compensation is as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Short-term benefits	¥ 720	¥ 903	\$ 6,429
Stock-based compensation		59	
Total	¥ 720	¥ 963	\$ 6,429

30. COMMITMENTS FOR EXPENDITURES

Commitments for expenditures are as follows:

	Millions of Yen		Thousands of U.S. Dollars
	2017	2016	2017
Commitments to purchase property, plant and equipment	¥ 834	¥ 887	\$ 7,446

31. CONTINGENT LIABILITIES

Not applicable.

32. SUBSEQUENT EVENT

(Acquisition of shares of Oxford Gene Technology IP Limited)

The Company acquired all shares of Oxford Gene Technology IP Limited.

The details of this acquisition are disclosed in "28. BUSINESS COMBINATION."

33. DISCLOSURES ON TRANSITION TO IFRS

The Group has prepared its consolidated financial statements in accordance with IFRS from the fiscal year ended March 31, 2017.

The most recent consolidated financial statements prepared in accordance with generally accepted accounting principles in Japan ("J-GAAP"), its previous GAAP, is for the year ended March 31, 2016, and the date of transition to IFRS was April 1, 2015.

(1) Exemptions of IFRS 1

IFRS 1 generally requires companies that are adopting IFRS for the first time to retrospectively apply standards under IFRS. However, IFRS 1 provides for exemptions to some of these requirements retrospectively, and first-time adopters may elect to use one or more of such exemptions. The Group has adopted such exemptions mainly to the following items:

1) Business combinations

IFRS 3 "Business Combinations" is not applied to business combinations occurring before the date of transition to IFRS.

2) Cumulative exchange differences on translating foreign operations

The cumulative exchange differences on translating foreign operations as of the date of transition to IFRS has been reclassified in its entirety to retained earnings.

3) Deemed cost

For certain items of property, plant and equipment, their fair values as of the date of transition to IFRS are used as their deemed costs.

4) Financial instruments

The designation in accordance with IFRS 9, "Financial Instruments" for financial instruments recognized prior to the date of transition to IFRS is based on relevant facts and circumstances that existed at the date of transition to IFRS.

5) Share-based payment

IFRS 2, "Share-Based Payment" has not been retrospectively applied to share-based payment vested prior to the date of transition to IFRS.

(2) Mandatory exceptions to the retrospective application of IFRS 1

IFRS 1 prohibits the retrospective application of IFRS to "estimates," "derecognition of financial assets and financial liabilities," "hedge accounting," "non-controlling interests," and "classification and measurement of financial assets." The Group applies these IFRSs to these items prospectively from the date of transition to IFRS.

(3) Reconciliations

For preparing the consolidated financial statements in accordance with IFRS, the Company has reconciled of the amounts in the consolidated financial statements prepared in accordance with J-GAAP into the amounts in accordance with IFRS. The effects of the transition from J-GAAP to IFRS on the Group's financial condition, operating results, and cash flows are as follows:

1) Reconciliation of equity

(i) Date of transition to IFRS (April 1, 2015)

(Unit: Millions of yen)

Account item of J-GAAP	J-GAAP	Reclassification	Differences in recognition and measurement	IFRS	Note	Account item of IFRS
Assets						
Current assets						
Cash and deposits	¥ 50,272	¥ (52)	¥ (605)	¥ 49,613	A	Cash and cash equivalents
		54,327	(665)	53,662	A	Trade and other receivables
Notes and accounts receivable-trade	53,038	(53,038)				
Lease investment assets	5,413	(5,413)				
Short-term investment securities	240	(240)				
		29,888	78	29,966	A	Inventories
Merchandise and finished goods	22,737	(22,737)				
Work in process	2,869	(2,869)				
Raw materials and supplies	4,281	(4,281)				
		298		298		Other short-term financial assets
		236	(13)	223	A	Income taxes receivable
Deferred tax assets	8,987	(8,987)				
Prepaid expenses	1,991	(1,991)				
Short-term loans receivable	1	(1)				
Others	4,890	1,399	194	6,484	A	Other current assets
Allowance for doubtful accounts	(575)	575				
Total current assets	154,148	(12,889)	(1,011)	140,248		Total current assets
Non-current assets						
Property, plant and equipment	59,061		(2,226)	56,835	A, B, D	Property, plant and equipment
Goodwill	12,114		(4,921)	7,192	A, D	Goodwill
Intangible assets (excluding goodwill)	11,668		(70)	11,598	A, D, E	Intangible assets
		1,931	5	1,937		Investments accounted for using the equity method
		3,901		3,901		Trade and other receivables
		6,112	327	6,440	F	Other long-term financial assets
Investment securities	7,174	(7,174)				
Long-term loans receivable	11	(11)				
Net defined benefit assets	960			960		Asset for retirement benefits
Long-term prepaid expenses	419	(419)				
Others	2,161	(443)	0	1,717	A	Other non-current assets
Deferred tax assets	267	8,987	(2,776)	6,478	A, K	Deferred tax assets
Allowance for doubtful accounts	(3)	3				
Total non-current assets	93,835	12,889	(9,662)	97,062		Total non-current assets
Total assets	¥ 247,983	¥	¥ (10,673)	¥ 237,310		Total assets

(Unit: Millions of yen)

Account item of J-GAAP	J-GAAP	Reclassif-ication	Differences in recognition and measurement	IFRS	Note	Account item of IFRS
Liabilities						
Current liabilities						
Notes and accounts payable-trade	¥ 15,965	¥ 22,098 (15,965)	¥ 677	¥ 22,776	A, H	Trade and other payables
		600	400	1,001	A, L	Other short-term financial liabilities
Current portion of lease obligations	50	(50)				
Income taxes payable	9,639		(220)	9,418	A, H	Income taxes payable
Deferred tax liabilities	101	(101)				
		456	(6)	450	A	Provisions
		10,228	128	10,357	A	Advance received
Accrued expenses	8,301		(164)	8,137	A	Accrued expenses
Provision for bonuses	6,119		11	6,130	A	Accrued bonuses
Provision for directors' bonuses	411	(411)				
Provision for product warranties	456	(456)				
Others	24,124	(16,004)	965	9,084	A, G	Other current liabilities
Total current liabilities	65,170	394	1,791	67,355		Total current liabilities
Non-current liabilities						
		199	143	342	A, L	Non-current liabilities
						Long-term financial liabilities
Lease obligations	199	(199)				
Provision for directors' retirement benefits	102	(102)				
Net defined benefit liabilities	460	102	(0)	562	A	Liability for retirement benefits
		124	2,187	2,312	J	Provisions
Others	3,507	(620)	208	3,094	G	Other non-current liabilities
Deferred tax liabilities	8,993	101	(3,426)	5,669	A, K	Deferred tax liabilities
Total non-current liabilities	13,262	(394)	(887)	11,980		Total non-current liabilities
Total liabilities	78,432		903	79,336		Total liabilities
Net assets						
Shareholders' equity						
						Equity
						Equity attributable to owners of the parent
Capital stock	10,483			10,483		Capital stock
Capital surplus	15,423	1,024	(107)	16,340	N	Capital surplus
Retained earnings	129,703		479	130,183	Q	Retained earnings
Treasury stock	(280)			(280)		Treasury stock
Total shareholders' equity	155,330					
Accumulated other comprehensive income	13,196		(11,949)	1,246	A, F, I, O	Other components of equity
				157,972		Total equity attributable to owners of the parent
Stock acquisition rights	1,024	(1,024)				
Minority interests			0	0	A	Non-controlling interests
Total net assets	169,550		(11,577)	157,973		Total equity
Total liabilities and net assets	¥ 247,983	¥	¥ (10,673)	¥ 237,310		Total liabilities and equity

(ii) As of March 31, 2016

(Unit: Millions of yen)

Account item of J-GAAP	J-GAAP	Reclassification	Differences in recognition and measurement	IFRS	Note	Account item of IFRS
Assets						
Current assets						
Cash and deposits	¥ 56,544	¥ (62)		¥ 56,481		Cash and cash equivalents
		57,652		57,652		Trade and other receivables
Notes and accounts receivable-trade	55,505	(55,505)				
Lease investment assets	8,535	(8,535)				
Short-term investment securities	299	(299)				
		35,623	¥ (18)	35,604		Inventories
Merchandise and finished goods	27,056	(27,056)				
Work in process	2,984	(2,984)				
Raw materials and supplies	5,581	(5,581)				
		615		615		Other short-term financial assets
		453		453		Income taxes receivable
Deferred tax assets	7,911	(7,911)				
Prepaid expenses	2,201	(2,201)				
Others	6,632	818		7,450		Other current assets
Allowance for doubtful accounts	(588)	588				
Total current assets	172,665	(14,388)	(18)	158,258		Total current assets
Non-current assets						
Property, plant and equipment	61,235		(1,953)	59,282	B, D	Property, plant and equipment
Goodwill	9,085		(2,164)	6,921	C, D	Goodwill
Intangible assets (excluding goodwill)	14,155		2,526	16,682	D, E	Intangible assets
		2,047	42	2,089	C	Investments accounted for using the equity method
		6,476		6,476		Trade and other receivables
		5,607	402	6,010	F	Other long-term financial assets
Investment securities	6,753	(6,753)				
Net defined benefit assets	582			582		Asset for retirement benefits
Long-term prepaid expenses	581	(581)				
Others	2,253	(324)		1,928		Other non-current assets
Deferred tax assets	329	7,911	(2,556)	5,684	K	Deferred tax assets
Allowance for doubtful accounts	(3)	3				
Total non-current assets	94,973	14,388	(3,702)	105,659		Total non-current assets
Total assets	¥ 267,638	¥	¥ (3,720)	¥ 263,917		Total assets

(Unit: Millions of yen)

Account item of J-GAAP	J-GAAP	Reclassif-ication	Differences in recognition and measurement	IFRS	Note	Account item of IFRS
Liabilities						Liabilities
Current liabilities						Current liabilities
Notes and accounts payable-trade	¥ 19,873	¥ 26,111 (19,873)	¥ 712	¥ 26,824	H	Trade and other payables
		644	143	788	L	Other short-term financial liabilities
Current portion of lease obligations	149	(149)				
Income taxes payable	6,817		(306)	6,511	H	Income taxes payable
Deferred tax liabilities	315	(315)				
		554		554		Provisions
		10,431		10,431		Advance received
Accrued expenses	6,864			6,864		Accrued expenses
Provision for bonuses	6,538			6,538		Accrued bonuses
Provision for directors' bonuses	526	(526)				
Provision for product warranties	554	(554)				
Others	24,254	(16,144)	1,273	9,383	G, M	Other current liabilities
Total current liabilities	65,895	176	1,823	67,896		Total current liabilities
Non-current liabilities		734		734		Non-current liabilities
						Long-term financial liabilities
Lease obligations	733	(733)				
Provision for directors' retirement benefits	102	(102)				
Net defined benefit liabilities	463	102		566		Liability for retirement benefits
		123	2,218	2,341	J	Provisions
Others	3,568	(617)	240	3,192	G	Other non-current liabilities
Deferred tax liabilities	8,778	315	(2,709)	6,384	K	Deferred tax liabilities
Total non-current liabilities	13,646	(176)	(250)	13,219		Total non-current liabilities
Total liabilities	79,542		1,573	81,116		Total liabilities
Net assets						Equity
Shareholders' equity						Equity attributable to owners of the parent
Capital stock	11,016			11,016		Capital stock
Capital surplus	15,957	1,097	(85)	16,969	N	Capital surplus
Retained earnings	155,562		3,812	159,375	Q	Retained earnings
Treasury stock	(285)			(285)		Treasury stock
Total shareholders' equity	182,251					
Accumulated other comprehensive income	4,745		(9,021)	(4,275)	F, I, O, P	Other components of equity
				182,800		Total equity attributable to owners of the parent
Stock acquisition rights	1,097	(1,097)				
Non-controlling interests	0			0		Non-controlling interests
Total net assets	188,095		(5,294)	182,801		Total equity
Total liabilities and net assets	¥ 267,638	¥	¥ (3,720)	¥ 263,917		Total liabilities and equity

2) Reconciliation of profit and comprehensive income

Year ended March 31, 2016

(Unit: Millions of yen)

Account item of J-GAAP	J-GAAP	Reclassification	Differences in recognition and measurement	IFRS	Note	Account item of IFRS
Net sales	¥ 253,157		¥ (535)	¥ 252,622	M	Net sales
Cost of sales	102,063		(130)	101,932	D, E, G, H, I, J, M	Cost of sales
Gross profit	151,093		(404)	150,689		Gross profit
Selling, general and administrative expenses	94,131	¥ (17,775)	(1,784)	74,571	C, D, E, G, H, I, J	Selling, general and administrative expenses
		17,775	(2,365)	15,409	E, G, H, I, J	Research and development expenses
		611	(0)	610		Other operating income
		605	(16)	588	D	Other operating expenses
Operating income	56,962	5	3,761	60,729		Operating profit
		374	7	382	L	Financial income
		96		96		Financial expenses
		(502)	36	(465)	C	Share of profit (loss) on equity method
		(2,743)	2	(2,741)		Foreign exchange gain (loss)
Non-operating income	963	(963)				
Non-operating expenses	3,582	(3,582)				
Extraordinary profits	1,082	(22)	(1,059)		I	
Extraordinary loss	764	(364)	(400)		F	
Income before income taxes	54,660		3,149	57,809		Profit before tax
		18,426	103	18,530	K	Income tax expenses
Income taxes-current	16,513	(16,513)				
Income taxes-deferred	1,912	(1,912)				
Profit	36,233		3,045	39,278		Profit
Other comprehensive income						Other comprehensive income
						Items that will not be reclassified subsequently to profit or loss
Unrealized loss on available-for-sale securities	(196)		(234)	(430)	F	Net gain (loss) on financial assets measured at fair value through other comprehensive income
Defined retirement benefit plans	(1,256)		719	(536)	I	Remeasurements of defined benefit plans
				(967)		Total
						Items that may be reclassified subsequently to profit or loss
Foreign currency translation adjustments	(6,999)		1,907	(5,091)	P	Exchange differences on translation of foreign operations
Deferred gains on derivatives under hedge accounting	1		(1)			
				(5,091)		Total
Total other comprehensive income	(8,450)		2,391	(6,059)		Total other comprehensive income (loss)
Comprehensive income	¥ 27,782	¥	¥ 5,436	¥ 33,219		Comprehensive income

(4) Notes to reconciliations

1) Reclassification

Reclassifications were changes to the presentation of the consolidated statement of financial position, the consolidated statement of income and the consolidated statement of comprehensive income, and therefore amounts of retained earnings were not affected.

In order to comply with IFRS, the Group reclassified the following major items.

- "Deferred tax assets" and "Deferred tax liabilities" presented as current items under J-GAAP have been presented as non-current items under IFRS.
- Leases receivable for which maturity is more than one year were, under J-GAAP, included in "Lease investment assets" presented as current items. These are included in "Trade and other receivables" as non-current items under IFRS.
- Research and development (R&D) expenses presented as part of "Selling, general and administrative expenses" under J-GAAP have been presented separately as "R&D expenses" under IFRS.

2) Differences in recognition and measurement

A. Change in reporting date of subsidiaries

In accordance with the change of the fiscal year end of part of certain subsidiaries from December 31 to March 31, the operating results of such subsidiaries for the three-month period from January 1, 2015, to March 31, 2015, were included in the consolidated statement of changes in equity by directly charging retained earnings under J-GAAP. However, under IFRS, the results are included in relevant accounts as of the date of transition.

B. Property, plant and equipment

Since the Group applied IFRS 1 exemptions to certain property, plant and equipment, their fair value as of the date of transition to IFRS have been used for measurement as deemed costs. As of the date of transition to IFRS, the previous carrying amounts under J-GAAP and the fair value of property, plant and equipment accounted for as deemed costs were ¥10,481 million and ¥9,602 million, respectively. These property, plant and equipment were measured by any of following method, which management believes as most appropriate, independent appraisal values, prices for similar assets, or discounted future cash flow method, which are categorized as Level 3 fair value.

C. Goodwill

Under J-GAAP, goodwill was amortized on a systematic basis over the period in which its effects were expected to occur, while under IFRS, goodwill has not been amortized since the date of transition to IFRS.

D. Impairment

Under J-GAAP, the need for impairment of goodwill was determined only in cases where indications of impairment were present. Under IFRS, however, impairment testing of goodwill is required at least once a one year, regardless of whether any indications of impairment exist. In addition, under J-GAAP, impairment losses on non-current assets were recognized at the excess of the carrying amount over the recoverable amount (i.e., the higher of the value in use and fair value, less costs of disposal) only when indications of impairment existed and the carrying amounts exceeded the undiscounted future cash flows expected to be generated from such assets. Under IFRS, however, impairment losses on non-current assets are recognized, upon impairment testing, in the amount of excess of the carrying amount of the non-current asset over the recoverable amount.

Major impairment losses arising at the date of transition as a result of the above differences between J-GAAP and IFRS include, in the EMEA segment, ¥5,907 million associated with a group of cash-generating units, including goodwill arising from the business combination of Sysmex Inostics GmbH and its subsidiary, and ¥1,033 million associated with cash-generating units, including goodwill arising from other business combinations, the total amount of which has been recorded as a reduction of the carrying amounts of property, plant and equipment; goodwill; and intangible assets. Value in use is determined by the discounted future cash flow method based on financial budgets and growth rates. The estimated period of the financial budgets is less than 5 years and the financial budgets are approved by the management of each cash-generating unit or a group of cash-generating units. Growth rates are determined by taking into consideration the average long-term growth rate of the market or the country in which the cash-generating group operates. The discount rate is determined based on the after-tax weighted-average capital cost for the market or the country in which each cash-generating unit or a group

of cash-generating units operate. 11.8% of the discount rate used for the calculation of value in use pertains to the cash-generating unit group, including goodwill arising from the business combination of Sysmex Inostics GmbH and its subsidiaries.

E. R&D expenses

Under J-GAAP, all expenditures for R&D were recognized as expenses when incurred. Under IFRS, however, expenditures for R&D that meet capitalization requirements are recognized as intangible assets.

F. Financial instruments

Under J-GAAP, securities without a market value were generally measured at cost, and impairment losses were recognized as necessary. Under IFRS, however, such securities are generally measured at fair value.

In addition, under J-GAAP, gains or losses on the sale of securities were recognized in profit or loss. Under IFRS, however, if an equity instrument is designated as a financial asset measured at fair value through other comprehensive income, the gains or losses on the sale of such equity instruments are recognized in other comprehensive income and not reclassified to profit or loss.

G. Unused paid leave

Under J-GAAP, unused paid leave was not accounted generally in accounting practices. Under IFRS, however, unused paid leave is recognized as a liability.

H. Levies

Under IFRS, as the timing of when to recognize the liabilities related to the payment of levies imposed by the government is clarified, liabilities are recognized according to the event obligating the payment.

I. Post-employment benefits

Under J-GAAP, actuarial differences and prior service costs were recognized as other comprehensive income and subsequently accounted for as expenses over certain future periods. Under IFRS, however, actuarial differences are recognized as other comprehensive income (remeasurements of defined benefit plans) when they occur, while prior service costs are recognized in profit or loss when incurred. On April 1, 2015, the Company adopted a cash balance plan as its defined benefit plan and transferred a portion of the plan to its defined contribution plan. In conjunction with this transition, under J-GAAP, the Company recognized prior service costs and gains and losses on liquidation as extraordinary gains in the previous fiscal year. Under IFRS, they are recognized as decreases in "Cost of sales," "Selling, general and administrative expenses," and "R&D expenses."

J. Special contributions to multi-employer plans

Under J-GAAP, special contributions to multi-employer plans were accounted for as expenses at the time of payment. Under IFRS, however, liabilities are recognized for the portion in which the amount to be obligated by the Group, which are clarified through the recalculation of finances of the plan and, subsequently, and such liabilities are reversed upon payment of the special contribution.

K. Deferred tax assets and deferred tax liabilities

Under J-GAAP, deferred tax asset associated with the elimination of unrealized gains and losses were calculated using the effective tax rate of the seller. Under IFRS, however, the effective tax rate of the buyer is used.

In addition, changes have occurred in deferred tax assets due to additional temporary differences arising from other reconciliation items and a review of the recoverability of all deferred tax assets.

L. Contingent consideration

Under J-GAAP, contingent consideration in a business combination was recognized when its grant or payment became certain. Under IFRS, however, contingent considerations are recognized at fair value as of the acquisition date.

M. Sale and leaseback transactions

Under J-GAAP, gains and losses on sales related to the sale and leaseback transactions of certain subsidiaries were recognized at the time of sales. Under IFRS, however, gains on sales are deferred and recognized throughout the lease term.

N. Costs of equity transactions

Under J-GAAP, costs of equity transactions were generally accounted for as expenses. Under IFRS,

however, costs attributable to equity transactions are deducted from equity.

O. Other components of equity

The exemption of IFRS 1 has been applied to the cumulative exchange differences on translating foreign operations. Accordingly, the cumulative exchange differences on translating foreign operations is deemed to be nil as of the date of transition to IFRS and the entire amount has been reclassified to retained earnings.

P. Translation adjustment related to other reconciliation items

Foreign exchange translation differences which are related to other reconciliation items of foreign operations have been adjusted.

Q. Retained earnings

The effects of the above reconciliation items on retained earnings are as follows:

	Millions of yen	
	Year ended March 31, 2016	Date of transition to IFRS (April 1, 2015)
Adjustments related to the change in reporting date of certain subsidiaries (see A)	¥ (1,837)	¥ (2,789)
Adjustments related to the deemed costs of property, plant and equipment (see B)	(879)	(879)
Adjustments related to the amortization of goodwill (see C)	1,544	
Adjustments related to impairment losses (see D)	(6,572)	(6,941)
Adjustments related to the capitalization of development expenses (see E)	4,240	2,321
Adjustments related to financial instruments (see F)	623	349
Adjustments related to unused paid leave (see G)	(1,448)	(1,239)
Adjustments related to levies (see H)	(403)	(391)
Adjustments related to remeasurements of defined benefit plans (see I)	208	1,400
Adjustments related to special contributions to multi-employer plans (see J)	(2,218)	(2,187)
Adjustments related to contingent consideration (see L)	(137)	(547)
Adjustments related to the amount of exchange differences on translating foreign operations (see O)	10,428	10,428
Others	26	207
Subtotal	3,573	(268)
Adjustments related to tax effects (see K)	239	747
Adjustments related to non-controlling interests	0	0
Total	¥ 3,812	¥ 479

(5) Notes on adjustments of cash flows

Year ended March 31, 2016

"Cash flows from operating activities" increased by ¥2,227 million and "Cash flows from investing activities" decreased by the same amount. The major adjustment is, under J-GAAP, all expenditures for R&D were classified under "Cash flows from operating activities." Under IFRS, however, capitalized development expenses are classified under "Cash flows from investing activities."